<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">BMC Infect Dis</journal-id><journal-title-group><journal-title>BMC Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786407</article-id><article-id pub-id-type="publisher-id">10442</article-id><article-id pub-id-type="doi">10.1186/s12879-025-10442-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Critical assessment of uncertainty in economic evaluations on influenza vaccines for the elderly population in Spain</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ortiz-de-Lejarazu Leonardo</surname><given-names>Ra&#x000fa;l</given-names></name><address><email>lejarazu@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>D&#x000ed;ez Domingo</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>de Miguel</surname><given-names>&#x000c1;ngel Gil</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Martin&#x000f3;n Torres</surname><given-names>Federico</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Marg&#x000fc;ello</surname><given-names>Esther Redondo</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>L&#x000f3;pez-Belmonte Claver</surname><given-names>Juan Luis</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Palomo-Jim&#x000e9;nez</surname><given-names>Paloma I.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Farr&#x000e9; Avell&#x000e0;</surname><given-names>J. Manel</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Abell&#x000e1;n Perpi&#x000f1;&#x000e1;n</surname><given-names>Jos&#x000e9; Mar&#x000ed;a</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><aff id="Aff1"><label>1</label>Centro Nacional de Gripe de Valladolid, GISRS (Global Influenza Surveillance and Response System), Valladolid, Spain </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0116vew40</institution-id><institution-id institution-id-type="GRID">grid.428862.2</institution-id><institution>Fundaci&#x000f3;n para el Fomento de la Investigaci&#x000f3;n Sanitaria y Biom&#x000e9;dica de la Comunitat Valenciana (FISABIO), </institution></institution-wrap>Valencia, Spain </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01v5cv687</institution-id><institution-id institution-id-type="GRID">grid.28479.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 2206 5938</institution-id><institution>Preventive and Public Health Department, </institution><institution>Rey Juan Carlos University, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/030eybx10</institution-id><institution-id institution-id-type="GRID">grid.11794.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0941 0645</institution-id><institution>Translational Paediatrics and Infectious Diseases Section, Paediatrics Department, </institution><institution>Hospital Cl&#x000ed;nico Universitario de Santiago de Compostela, </institution></institution-wrap>Santiago de Compostela, Spain </aff><aff id="Aff5"><label>5</label>Vaccines, Infections and Pediatrics Research Group (GENVIP), Healthcare Research Institute of Santiago de Compostela, Santiago de Compostela, 15706 Spain </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/026h6d543</institution-id><institution-id institution-id-type="GRID">grid.423847.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 1882 2393</institution-id><institution>International Healthcare Centre of Ayuntamiento de Madrid, </institution></institution-wrap>Madrid, 28006 Spain </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ca2c886</institution-id><institution-id institution-id-type="GRID">grid.413448.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9314 1427</institution-id><institution>CIBER of Respiratory Diseases (CIBERES), </institution><institution>Instituto de Salud Carlos III, </institution></institution-wrap>Madrid, 28029 Spain </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00g51ew42</institution-id><institution-id institution-id-type="GRID">grid.476745.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 4907 836X</institution-id><institution>Sanofi, Market Access, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00g51ew42</institution-id><institution-id institution-id-type="GRID">grid.476745.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 4907 836X</institution-id><institution>Sanofi, Medical Affairs, </institution></institution-wrap>Barcelona, Spain </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03p3aeb86</institution-id><institution-id institution-id-type="GRID">grid.10586.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2287 8496</institution-id><institution>Applied Economics Department, Economics &#x00026; Enterprise Faculty, </institution><institution>University of Murcia, </institution></institution-wrap>Murcia, Spain </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><elocation-id>152</elocation-id><history><date date-type="received"><day>4</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>2</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Influenza is a seasonal infection with a huge impact on morbidity and mortality in older adults, for whom vaccination is recommended. New influenza vaccines for this population have been introduced in Spain in the past 5 years, and a number of cost-effectiveness analyses (CEA) have been published to aid healthcare decision-making. The objective of this study was to assess possible sources of uncertainty in the CEAs of influenza vaccines for the older adults in Spain.</p></sec><sec><title>Methods</title><p id="Par2">A systematic review was performed to identify Spanish CEAs published since 2016. Potential sources of structural, methodologic and parametric uncertainty in CEA results were systematically analysed using the TRansparent Uncertainty ASsessmenT (TRUST) Tool, quality assessment checklists, and the WHO guidance on economic evaluations of influenza vaccine strategies. The primary sources of efficacy/effectiveness were analysed in depth to ascertain whether they could support the conclusions of the respective CEAs.</p></sec><sec><title>Results</title><p id="Par3">Seven CEAs were included. Overall, they were designed and performed in accordance with the applicable guidelines; however, some critical sources of uncertainty were detected, mainly: (1) the choice and use of efficacy/effectiveness data (real-world single season studies, meta-analyses including studies with high risk of bias and/or high heterogeneity with biased interpretation); (2) use of fewer than 5 seasons to estimate influenza burden; (3) generalized use of influenza-like illness data to estimate effectiveness and burden, among others.</p></sec><sec><title>Conclusions</title><p id="Par4">Seemingly well-designed studies may conceal important sources of uncertainty that affect the results. This must be taken into account when interpreting results to support decision-making.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12879-025-10442-3.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cost-effectiveness analysis</kwd><kwd>Influenza vaccination</kwd><kwd>Uncertainty analysis</kwd><kwd>TRUST Tool</kwd><kwd>Quality of evidence</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par31"> Influenza is an annual viral illness that causes seasonal epidemics [<xref ref-type="bibr" rid="CR1">1</xref>]. In Spain, it costs up to &#x020ac;145&#x02013;1,000&#x000a0;million annually [<xref ref-type="bibr" rid="CR2">2</xref>]. Hospitalizations, mainly in high-risk groups, are the key cost-driver [<xref ref-type="bibr" rid="CR2">2</xref>]. The population over 65 is especially susceptible to severe complications [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>], so the WHO recommends seasonal immunization in this group [<xref ref-type="bibr" rid="CR5">5</xref>], and the Spanish national healthcare system (NHS) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>] has implemented a vaccination program to prevent severe infections, hospitalizations, and deaths. Standard dose quadrivalent (QIV) vaccines are effective in preventing influenza and its complications [<xref ref-type="bibr" rid="CR8">8</xref>]. However, various studies have reported that these vaccines are less effective in elderly adults due to immunosenescence [<xref ref-type="bibr" rid="CR9">9</xref>]. For this reason, adjuvanted QIV (aQIV) and high-dose QIV (HD-QIV) vaccines have been developed to specifically address immunosenescence issues, but are more expensive. Cell-cultured (QIVc) and, more recently, recombinant vaccines (QIVr) aim to overcome viral mutation occurring in egg-based manufacturing process.</p><p id="Par32">Spain has a decentralized healthcare system in which each autonomous region can decide the type of vaccine to be used in target influenza vaccination populations. However, due to budget constraints, each region must carefully evaluate the cost-effectiveness of all available options in order to balance resource allocation with clinical results [<xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, critical reading and interpretation of available economic evaluations is paramount in the decision-making process.</p><p id="Par33">Cost-effectiveness analyses (CEA) measure the incremental health gains and costs of interventions in order to assess the efficiency of funding a new healthcare intervention with respect to other established ones in a specific setting. Differences in model type, methods, and parameter values introduce uncertainty, and policymakers require thorough description and quantification to understand the strengths and limitations of the analysis [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par34">For this purpose, we systematically reviewed and analysed the CEAs of influenza vaccines for the older adults (&#x02265;&#x02009;60 years) published in Spain to: (1) assess whether these evaluations were carried out following best practices in economic evaluation of influenza vaccines, (2) identify possible sources of uncertainty that may affect the results and should be considered in decision making.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par35">To fulfil our objective, we first collected the available studies assessing the cost-effectiveness of influenza vaccines in Spain, then we have critically analyzed different uncertainty sources (i.e., parametric, structural and methodological) surrounding each of the identified studies using an influenza-adapted TRUST Tool. When analysing the parametric uncertainty of each CEA we have also retrieved all efficacy/effectiveness sources and appraised their methodological quality by using the appropriate validated checklist (RoB2, AMSTAR-2, or NOS). The study flowchart is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.</p><p id="Par36">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Study flowchart AMSTAR-2: A Measurement Tool to Assess Systematic Reviews-2; HEOR: Health-Economics and Outcomes Research; TRUST: TRansparent Uncertainty ASsessmenT; WHO: World Health Organization; RoB 2: Risk of bias 2; NOS: Newcastle-Ottawa Scale</p></caption><graphic xlink:href="12879_2025_10442_Fig1_HTML" id="MO1"/></fig></p><sec id="Sec3"><title>Systematic review</title><p id="Par37">We performed a systematic review of the literature reporting complete economic evaluations (CEE), i.e., cost-effectiveness, cost-utility analyses, and/or cost-benefit analyses of influenza vaccines in the population aged&#x02009;&#x0003e;&#x02009;60 years in Spain, following the recommendations of the Cochrane Handbook for Systematic Review of Interventions [<xref ref-type="bibr" rid="CR12">12</xref>]. PubMed (<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</ext-link> ), Scopus (<ext-link ext-link-type="uri" xlink:href="https://www.scopus.com/home.uri">https://www.scopus.com/home.uri</ext-link> ), Web of Sciente (WoS), and the Biblioteca Virtual de Salud (<ext-link ext-link-type="uri" xlink:href="https://bvsalud.isciii.es/">https://bvsalud.isciii.es/</ext-link>) were searched for studies published since 2016 in Spanish or English. The search was closed on November 7th, 2022. One reviewer screened the references, with the others being available for resolving doubts. The complete definition of the review question, search terms and strategy, and the full selection criteria are detailed in Supplementary Material 1.</p></sec><sec id="Sec4"><title>Critical analysis of the economic evaluations</title><p id="Par38">Each study was critically reviewed by three independent investigators to verify their the compliance with the WHO &#x0201c;Guidance on the economic evaluation of influenza vaccination&#x0201d; [<xref ref-type="bibr" rid="CR13">13</xref>] and the TRansparent Uncertainty ASsessmenT (TRUST) Tool [<xref ref-type="bibr" rid="CR14">14</xref>] was used to identify possible sources of uncertainty in CEEs. A consensus of the most relevant sources of uncertainty in each study was reached through discussion among the three investigators.</p><p id="Par39">As the TRUST Tool has not been developed specifically for influenza vaccine models, we first created a theoretical framework for the tool by collecting all theoretical sources for TRUST cited by Grimm et al. 2020 [<xref ref-type="bibr" rid="CR14">14</xref>] and the recommendations from the WHO guidance [<xref ref-type="bibr" rid="CR13">13</xref>] and merging them with unique definitions to give all investigators a common standard for their analysis.</p><p id="Par40">It is also important to correctly define the terminology used to describe the types of uncertainty assessed in this article, as this is sometimes confusing in the literature:</p><sec id="Sec5"><title>Model or structural uncertainty</title><p id="Par41">Model uncertainty arises from the choice of the model (e.g., dynamic or static), its structure, and how health states are connected. It also analyses whether the model correctly assesses the main objective [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. Issues such as transparency, biases in modelling choices, and uncertainties around key structural assumptions (e.g., time horizons or exclusion of health states) may need further exploration, e.g., through sensitivity analyses [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec><sec id="Sec6"><title>Methodological uncertainty</title><p id="Par42">Methodological uncertainty arises from the various economic evaluation methods used to estimate use of resources and the health outcomes of the assessed interventions. It can arise from the chosen perspective, time horizon, analytic technique (CEA, CEU), discount rate, etc [<xref ref-type="bibr" rid="CR11">11</xref>]. Methodologic inconsistencies or deviations from standardized procedures warrant scenario analyses or the incorporation of expert opinion to buffer their impact on results [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec><sec id="Sec7"><title>Parameter uncertainty</title><p id="Par43">This uncertainty arises from the specific data used to populate the model, and therefore involves efficacy and/or effectiveness data, unit costs, resource use/costs, epidemiological burden of the disease, etc [<xref ref-type="bibr" rid="CR17">17</xref>]. Parameter uncertainty is a second-order uncertainty and relates to the fact that the probabilities that govern outcomes, being estimated quantities, are themselves uncertain [<xref ref-type="bibr" rid="CR15">15</xref>]. Parameter uncertainty also encompasses imprecision, such as wide confidence intervals or immature data, and may reflect data biases or indirectness. To address this, probabilistic sensitivity analysis (PSA) should be used to quantify the effects of parameter uncertainty [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec><sec id="Sec8"><title>Management of uncertainty</title><p id="Par44">Managing uncertainty in CEAs is crucial [<xref ref-type="bibr" rid="CR17">17</xref>]. Sensitivity and scenario analyses, including deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA), are of great importance [<xref ref-type="bibr" rid="CR17">17</xref>]. In DSA, one parameter at a time is varied within its realistic limits, often from 95% confidence intervals. This clarifies the impact of a specific variable on cost-effectiveness. PSA, a multivariate analysis simultaneously varies all variables based on probability distributions, thereby creating cost-effectiveness planes and acceptability curves relative to a defined willingness-to-pay threshold for each country.</p></sec></sec><sec id="Sec9"><title>Assessment of the quality of the primary effectiveness sources</title><p id="Par45">The data sources for vaccine effectiveness in each CEE were identified, retrieved, and analysed as follows: (1) three investigators independently evaluated the global quality of each publication by applying one of the most commonly used [<xref ref-type="bibr" rid="CR18">18</xref>] validated quality appraisal checklists, according to the type of study (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>); (2) Each source and the conclusions of the previous technical verification were then critically reviewed by a clinical expert, who examined aspects specific to influenza that are not evaluated in quality checklists, such as case definition, number of seasons included, and population subgroups. (3) All studies, analyses, and conclusions were shared and discussed in two investigator meetings held in 2023, in which the participants agreed on their conclusions and decided whether the effectiveness data were sourced from the best studies available at the time of model development, and whether original data were correctly used in the model.</p><p id="Par46">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Quality assessment checklist used according to the type of study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Type of study</th><th align="left">Checklist <bold>[</bold><xref ref-type="bibr" rid="CR18">18</xref><bold>]</bold></th></tr></thead><tbody><tr><td align="left">Randomized controlled trial</td><td align="left">RoB 2 [<xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr><td align="left">Observational study</td><td align="left">NOS [<xref ref-type="bibr" rid="CR20">20</xref>]</td></tr><tr><td align="left">Systematic review with meta-analysis</td><td align="left">AMSTAR-2 [<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>AMSTAR-2 </italic>A MeaSurement Tool to Assess systematic Reviews 2,<italic>&#x000a0;NOS </italic>Newcastle-Ottawa Score,<italic>&#x000a0;RoB 2 </italic>Risk of Bias 2</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Analysed studies</title><p id="Par47">The literature search yielded 163 primary studies, of which&#x000a0;94 were unique references; 85 were excluded by title/abstract (mainly because they were centred in a different population or used other types of economic evaluations) and 9 were included for full-text reading. Six were finally included. However, an additional study that met the selection criteria was published after closing the search and was added manually. The Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) flowchart for the selection process and the list of excluded studies and the motives for exclusion are presented in Supplementary Material 2.</p><p id="Par48">The main characteristics of the included studies are detailed in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par49">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Main characteristics of the economic evaluations analysed</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Reference</th><th align="left">Type of economic evaluation</th><th align="left">Type of model</th><th align="left">Evaluated vaccine type&#x000a0;(unit price)<break/>Reference year</th><th align="left">Age groups</th><th align="left">Time horizon</th><th align="left">Perspective</th><th align="left">Results and conclusions</th><th align="left">Sponsored by</th></tr></thead><tbody><tr><td align="left"><bold>Garcia et al. 2016</bold> [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">Cost-utility</td><td align="left">Static decision tree</td><td align="left"><p>QIV (&#x020ac;9.50) vs. TIV (&#x020ac;7.00)</p><p>Year 2014</p></td><td align="left">0&#x02013;4, 5&#x02013;17, 18&#x02013;49, 50&#x02013;64, 65&#x02013;69, 70&#x02013;74, 75&#x02013;79, 80&#x02013;84 and 85+</td><td align="left">100 years</td><td align="left">NHS and societal</td><td align="left">Compared to TIVs, QIV reduced more influenza cases and influenza-related complications and deaths during B-mismatch periods. ICER was &#x020ac;8,748/QALY. DSA showed that mismatch with the B lineage included in the TIV was the main driver for ICER. <italic>Authors conclude that replacing TIVs with QIV in Spain could be a cost-effective healthcare intervention.</italic></td><td align="left">GlaxoSmithKline</td></tr><tr><td align="left"><bold>Crep&#x000e9;y et al. 2020</bold> [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left">Cost-utility and budgetary impact</td><td align="left">Dynamic transition model</td><td align="left"><p>QIV (&#x020ac;9.50) vs. TIV (&#x020ac;7.15)</p><p>Year 2017</p></td><td align="left">&#x0003c;&#x02009;65 high risk and 65+</td><td align="left">1 year</td><td align="left">NHS and societal</td><td align="left">Replacing TIV with QIV may have prevented 138,707 influenza B cases per season and avoided 10,748 outpatient visits, 3,179 hospitalizations, and 192 deaths. This could save &#x020ac;532,768 in outpatient visits, &#x020ac;13&#x000a0;million in hospitalizations, and &#x020ac;3&#x000a0;million in influenza-related deaths per year. An additional &#x020ac;5&#x000a0;million associated with productivity loss could be saved per year from the societal perspective. The ICER was &#x020ac;1,527/QALY. <italic>Thus</italic>,<italic> authors consider QIV to be cost-effective compared to TIV.</italic></td><td align="left">Sanofi Pasteur</td></tr><tr><td align="left"><bold>Ruiz-Arag&#x000f3;n et al. 2020</bold> [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">Cost-utility</td><td align="left">Static decision tree</td><td align="left"><p>eQIV (&#x020ac;6.00) vs. cQIV&#x000a0;(&#x020ac;7.50)</p><p>Year not stated</p></td><td align="left">9&#x02013;17; 18&#x02013;60; 60&#x02013;64</td><td align="left">1 year&#x02009;+&#x02009;long-term consequences (indirect costs)</td><td align="left">NHS and Societal</td><td align="left">Using QIVc instead of QIVe was associated with 16,221 fewer symptomatic cases, 4,522 fewer primary care visits, 1,015 fewer emergency room visits, and 88 fewer hospitalizations. From a societal perspective, QIVc was more effective and less expensive compared to QIVe, leading to a cost saving of &#x020ac;3.4&#x000a0;million. From a public payer perspective, the ICER for QIVc vs. QIVe was &#x020ac;12,852/QALY. <italic>Authors conclude that QIVc offers a cost-effective alternative to QIVe and should be considered for people aged 9&#x02013;64 at high-risk of influenza complications</italic>.</td><td align="left">Seqirus</td></tr><tr><td align="left"><bold>Redondo et al. 2021 </bold>[<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left">Cost-utility</td><td align="left">Static decision tree</td><td align="left"><p>HD-QIV (&#x020ac;32.00) vs. aQIV (&#x020ac;8.00)</p><p>Year 2020</p></td><td align="left">65+</td><td align="left">1 season</td><td align="left">NHS</td><td align="left">Switching from aTIV strategy to HD-QIV would prevent 36,476 cases of influenza, 5,143 visits to GP, 1,054 visits to the ED, 9,193 hospitalizations due to influenza or pneumonia, and 357 deaths due to influenza. This would result in a gain of 3,514 life years and 3,167 QALYs. Healthcare costs increased by &#x020ac;78,874,301, leading to an incremental cost-effectiveness ratio of &#x020ac;24,353/QALY. <italic>Authors conclude that HD-QIV would be cost-effective compared to aTIV in the population under study.</italic></td><td align="left">Sanofi Pasteur</td></tr><tr><td align="left"><bold>Ruiz-Arag&#x000f3;n et al. 2022 </bold>[<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left">Cost effectiveness and Cost utility</td><td align="left">Static decision tree</td><td align="left"><p>aQIV (&#x020ac;13.00) vs. HD-QIV (&#x020ac;25.00)</p><p>Year 2021</p></td><td align="left">65+</td><td align="left">1 year&#x02009;+&#x02009;long-term consequences (indirect costs)</td><td align="left">NHS and Societal</td><td align="left">aQIV vs. HD-QIV yielded reductions of 5405 symptomatic cases, 760 primary care visits, 171 emergency room visits, 442 hospitalizations, and 26 deaths in Spain each year. LYs and QALYs increases by 260 and 206, respectively, each year. Savings from a direct medical payer perspective are &#x020ac;63.6&#x000a0;million, driven by the lower aQIV vaccine price and a minor advantage in effectiveness. From a societal perspective, savings increase to &#x020ac;64.2&#x000a0;million. When vaccine prices are assumed equal, aQIV remains dominant compared to HD-QIV. Potential savings are estimated at over &#x020ac;61&#x000a0;million in vaccine costs alone. <italic>Authors affirm that aQIV is a highly cost-effective alternative to HD-QIV for people aged 65&#x02009;+&#x02009;in Spain.</italic></td><td align="left">Seqirus</td></tr><tr><td align="left"><bold>Fochesato et al.</bold>,<bold> 2022 </bold>[<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left">Cost-utility</td><td align="left">Dynamic transition model</td><td align="left"><p>aQIV (&#x020ac;13.00) vs. SD-QIV (&#x020ac;9.50)</p><p>Year 2021</p></td><td align="left">6&#x02013;23 months; 2&#x02013;6 years; 7&#x02013;17 years; 18&#x02013;64 years; 65+</td><td align="left">1 season&#x02009;+&#x02009;long-term consequences (indirect costs)</td><td align="left">NHS and Societal</td><td align="left">Replacing QIVe with aQIV would prevent, on average, 43,664 complicated cases, 1111 hospitalizations, and 569 deaths (rVE&#x02009;=&#x02009;34.6%) or 19,104 cases of influenza complications, 486 hospitalizations, and 252 deaths (rVE&#x02009;=&#x02009;13.9%). When the rVE of aQIV vs. QIVe is 34.6%, ICER was &#x020ac;2240/QALY from the payer perspective; from the societal perspective, aQIV was cost saving compared with QIVe. With an rVE of 13.9%, ICER was &#x020ac;6694/QALY and &#x020ac;3936/QALY from the payer and societal perspective, respectively. <italic>According to authors</italic>,<italic> aQIV in the Spanish older adults is cost effective for the Spanish NHS compared to QIVe.</italic></td><td align="left">Seqirus</td></tr><tr><td align="left"><bold>Ruiz Arag&#x000f3;n et al. 2023</bold> [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left">Cost-utility</td><td align="left">Static decision tree</td><td align="left"><p>QIVr (&#x020ac;25.00) vs. aQIV (&#x020ac;13.00)</p><p>Year 2021</p></td><td align="left">65+</td><td align="left">1 season&#x02009;+&#x02009;long term consequences (indirect costs)</td><td align="left">Societal</td><td align="left">Based on current tender prices and assuming QIVr/aQIV rVE of 10.7%, the ICER for QIVr was &#x020ac;101,612.41/QALY. Authors also estimated that to meet the Spanish WTP threshold of &#x020ac;25,000/QALY, rVE for QIVr vs. aQIV should be 34.1%. In their PSA, 99.7% of simulations for QIVr were higher than the WTP curve. <italic>QIVr is not currently a cost-effective influenza vaccine option relative to aQIV for elderly individuals in Spain.</italic></td><td align="left">Seqirus</td></tr></tbody></table><table-wrap-foot><p><italic>aQIV</italic> Adjuvated-Quadrivalent Influenza Vaccine, <italic>aTIV</italic> Adjuvated Trivalent Influenza Vaccine, <italic>DSA</italic> Deterministic Sensitivity Analysis, <italic>ED</italic> Emergency Department, <italic>GP</italic> General Practice, <italic>HD-QIV</italic> High-Dose Quadrivalent Influenza Vaccine, <italic>NHS</italic> National health service, <italic>PSA</italic> Probabilistic sensitivity analysis, <italic>rVE</italic> relative Vaccine Effectiveness, <italic>QIV</italic> Quadrivalent Influenza Vaccine, <italic>QIVe</italic> egg-based Quadrivalent Influenza Vaccine, <italic>QIVc</italic> cell-based Quadrivalent Influenza Vaccine, <italic>QIVr</italic>&#x000a0;Recombinant Quadrivalent Influenza Vaccine <italic>SD-QIV</italic> Standard-Dose Quadrivalent Influenza Vaccine, <italic>TIV</italic> Trivalent Influenza Vaccine, <italic>WTP</italic> Willingness to pay</p></table-wrap-foot></table-wrap></p><p id="Par50">The quality appraisal of the analysed studies according to validated checklists is reported in the Supplementary Material 3. The quality of the sources used by each study was highly heterogeneous, ranging from high quality RCTs [<xref ref-type="bibr" rid="CR22">22</xref>] to critically-low-quality systematic reviews with meta-analysis [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>]. Some sources could not be evaluated because they were not available or did not offer sufficient detail [<xref ref-type="bibr" rid="CR27">27</xref>]. However, the general methodologic quality assessment did not capture all relevant aspects concerning influenza vaccines, for which a thorough analysis of these aspects was carried out when applying the TRUST tool.</p></sec><sec id="Sec12"><title>Description of sources of uncertainty in the included CEA</title><p id="Par51">As described, the TRUST [<xref ref-type="bibr" rid="CR14">14</xref>] tool and WHO guidance [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR28">28</xref>] were used to assess potential uncertainty in several domains. Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> describes the analysis of sources of potential parameter uncertainty and Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> describes the assessment of methodological uncertainty. The detailed analysis by study is reported in Supplementary Material 4. Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref> analyses the primary sources of effectiveness data used in each economic study.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>TRUST tool analysis of sources of parametric uncertainty </p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" rowspan="2">Burden of illness (&#x0003c;&#x02009;5 seasons)</th><th align="left" colspan="2">Characteristics of the source of effectiveness data<sup>a</sup></th><th align="left" rowspan="2">Baseline utility and disutility values</th><th align="left" rowspan="2">Resource use &#x00026; costs data</th><th align="left" rowspan="2">Other</th><th align="left" rowspan="2">Sensitivity analyses</th></tr><tr><th align="left">Design of sources</th><th align="left"/></tr></thead><tbody><tr><td align="left"><bold>Garc&#x000ed;a et al. 2016 </bold>[<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">GP or ED 1 year; hospitalization and death 6 years</td><td align="left">&#x02022; QIV VE: Tricco et al. 2013, many included studies have uncertain results with 95%CIs crossing RR&#x02009;=&#x02009;1; heterogeneity is moderate</td><td align="left"><p>GP or ED cases: ILI.</p><p>Hospitalization and death: Lab-confirmed influenza and ILI</p></td><td align="left">NRUD</td><td align="left">Includes children, but productivity loss for working parents is not calculated</td><td align="left">&#x000a0;NRUD</td><td align="left">Parameters tested in DSA and their intervals were not listed. Authors state that the parameters most affecting the ICER of QIV were: the circulation of type A influenza, and the potential B lineage mismatch; but tornado plot is not provided. PSA was performed but probability distributions were not declared, results are represented as acceptability curve</td></tr><tr><td align="left"><bold>Cr&#x000e9;pey et al. 2020 </bold>[<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left">NRUD</td><td align="left">&#x02022; TIV VE and additional B strain VE: Meta-analysis Diaz Granados et al. 2012 and CDC unpublished data at the time of the study.</td><td align="left">NRUD</td><td align="left">NRUD</td><td align="left"><p>Includes children but productivity loss for working parents is not calculated.</p><p>Resource costs derived from eSalud<sup>b</sup>, primary data sources and data processing not explained</p></td><td align="left">&#x000a0;NRUD</td><td align="left">DSA variation intervals and PSA probability distributions were not informed. PSA is not represented as an acceptability curve</td></tr><tr><td align="left"><bold>Ruiz Arag&#x000f3;n et al. 2020 </bold>[<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">3 seasons (2014/15- 2017/18)</td><td align="left"><p>&#x02022; QIVc and QIVe A/H1N1 and B: Belongia et al. 2016 meta-analysis: only includes test-negative design studies</p><p>&#x02022; QIVc A/H3N2, from Boikos et al. 2019 from single season unpublished observational study.</p></td><td align="left">QIVc: ILI</td><td align="left">Model age groups do not correspond to the age groups defined in the data source; method of mapping original utility values on the model groups should have been explained.</td><td align="left">Resource cost derived from official bulletins of two regions, reason for choice and management of costs not given</td><td align="left">Vaccine coverage from data-on-file provided by the intervention manufacturer, while vaccination coverage is publicly available from official Spanish sources.</td><td align="left">A one-way deterministic sensitivity analysis (DSA) was conducted where model parameters were varied by &#x000b1;&#x02009;10%, which is not the recommended method in applicable guidelines. The tornado plot representing the variables having the highest impact is presented. Also, PSA was carried out and represented as a cost-effectiveness plane (scatterplot). .</td></tr><tr><td align="left"><bold>Redondo et al. 2021 </bold>[<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left">NRUD</td><td align="left">&#x02022; rVE aTIV vs. SD-TIV: Puig Barber&#x000e1; et al. 2016 RWE for 1 season</td><td align="left">Lab-confirmed influenza; ILI for HD-QIV vs. SD-QIV protection against hospitalization</td><td align="left">NRUD</td><td align="left">NRUD</td><td align="left">&#x000a0;NRUD</td><td align="left"><p>A scenario analysis is provided testing a broader definition of influenza complication for hospitalizations and 0% rVE for aTIV vs. SD-TIV.</p><p>All upper and lower bound used in the DSA are detailed in the paper, as well as probability distributions used in the PSA, making the sensitivity analysis highly transparent. Sensitivity analyses are presented for both base case and alternative scenario. DSA is presented by tornado diagram, and PSA by acceptability curve, while the cost-effectiveness plane was not represented</p></td></tr><tr><td align="left"><bold>Ruiz Arag&#x000f3;n et al. 2022 </bold>[<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left">3 seasons (2017/18&#x02013;2019/20)</td><td align="left">&#x02022; High-heterogeneity meta-analysis not based on systematic search</td><td align="left">Not specified</td><td align="left">No explanation of method used to map disutility values from original age groups to model age groups</td><td align="left">Resource costs derived from official bulletins of three regions, reason for choice not given. Middle cost used.</td><td align="left">&#x000a0;NRUD</td><td align="left">Both PSA and DSA have been carried out; however, DSA input data and probability distributions used in the PSA have not been reported.</td></tr><tr><td align="left"><bold>Fochesato et al. 2022 </bold>[<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left">Not specified</td><td align="left">&#x02022; VE for QIVe Belongia et al. 2016 meta-analysis: only includes test-negative design studies</td><td align="left">Alternative scenario ILI</td><td align="left">Italian data used even though Spanish data were available</td><td align="left">Resource cost derived from official bulletins of different regions, reason for choice and management of costs not given</td><td align="left">Contact rates from Italy transferred to Spanish model. Data were considered transferable when at least one circulating strain was present in both countries simultaneously. However, this strain was usually H1N1 A, subtype against which all vaccines have high effectiveness for the elderly. For four seasons, circulating strains did not coincide - either H3N2 or B (or both) were present in one of the countries but absent in the other. Model calibration not presented.</td><td align="left">An alternative scenario was estimated with rVE coming from Coleman et al. 2021. DSA and PSA are carried out for both the base case and the alternative scenario. Upper and lower bounds for sensitivity analyses are detailed. DSA is represented through tornado plots and the PSA is represented as a cost-effectiveness scatter plot.</td></tr><tr><td align="left"><bold>Ruiz Arag&#x000f3;n et al. 2023 </bold>[<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left">3 seasons (2017/18&#x02013;2019/20)</td><td align="left">&#x02022; RWE of QIVr vs. aTIV based on only 1 season</td><td align="left">Not specified</td><td align="left">NRUD</td><td align="left">Resource cost derived from official bulletins of three regions, reason for choice and management of costs not given</td><td align="left">&#x000a0;NRUD</td><td align="left">DSA and PSA were carried out to test the robustness of the model, which are both represented in the paper with a tornado plot and the cost-effectiveness plane, respectively. While DSA upper and lower bounds were presented, their source is not cited. Probability distribution for PSA is not presented either. Considering the uncertainty of the available effectiveness data, authors carried out a scenario analysis in which they fixed the ICER at 25,000&#x020ac;/QALY, which is commonly considered as the acceptability threshold in Spain, and calculated back the necessary rVE for QIVr vs. aQIV, it resulted in 34.12%, authors discuss that this efficacy has not been reached even in the RCT.</td></tr></tbody></table><table-wrap-foot><p><italic>aTIV</italic>&#x000a0;Adjuvated-TIV, <italic>CDC</italic>&#x000a0;Centre for Disease Control, <italic>GP</italic>&#x000a0;General practice, <italic>ED</italic>&#x000a0;Emergency department, <italic>HD-QIV</italic>&#x000a0;High-dose-QIV, <italic>ILI</italic>&#x000a0;Influenza-like illness, <italic>NRUD</italic>&#x000a0;No relevant uncertainties detected, <italic>RWE</italic>&#x000a0;Real world evidence, <italic>QIV</italic>&#x000a0;Quadrivalent inactivated vaccine, <italic>QIVc</italic>&#x000a0;cell-based-QIV, <italic>QIVe</italic>&#x000a0;egg-based-QIV, <italic>QIVr</italic>&#x000a0;recombinant-QIV, <italic>SD-TIV</italic>&#x000a0;Standard-dose-TIV, <italic>TIV</italic>&#x000a0;Trivalent inactivated vaccine</p><p><sup>a</sup>Quality and appropriateness of sources of effectiveness were assessed as described in Methods</p><p><sup>b</sup>eSalud is a Spanish online repository of costs from different sources, mainly official bulletins, and published literature</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>TRUST tool analysis of sources of methodological uncertainty: outcome presentation and uncertainty management</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" rowspan="2">Perspective</th><th align="left" rowspan="2">Disaggregated outcomes (costs and benefits)</th><th align="left" rowspan="2">Disaggregated ICER (NHS and societal perspectives)</th><th align="left" rowspan="2">Scenario analysis</th><th align="left" colspan="2">Deterministic sensitivity analysis</th><th align="left" colspan="2">Probabilistic sensitivity analysis</th><th align="left">Acceptability threshold</th></tr><tr><th align="left">Presentation of input data (upper/lower limits and sources)</th><th align="left">Graphic representation (Tornado plot)</th><th align="left">Presentation of input data (distributions)</th><th align="left">Graph</th><th align="left"/></tr></thead><tbody><tr><td align="left"><bold>Garc&#x000ed;a et al. 2016 </bold>[<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">NRUD</td><td align="left">NRUD</td><td align="left">NRUD</td><td align="left">NA</td><td align="left">Not presented</td><td align="left">No graph</td><td align="left">Not presented</td><td align="left">Only acceptability curve</td><td align="left">&#x020ac;20,000/QALY and &#x020ac;30,000/QALY</td></tr><tr><td align="left"><bold>Cr&#x000e9;pey et al. 2020 </bold>[<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left">NRUD</td><td align="left">NRUD</td><td align="left">NRUD</td><td align="left">NA</td><td align="left">Not presented</td><td align="left">Tornado plot</td><td align="left">Distributions</td><td align="left">No graph</td><td align="left">&#x020ac;25,000/QALY</td></tr><tr><td align="left"><bold>Ruiz Arag&#x000f3;n et al. 2020 </bold>[<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">NRUD</td><td align="left">NRUD</td><td align="left">NRUD</td><td align="left">NA</td><td align="left">Variation based on arbitrary intervals: &#x000b1;10%, does not follow ISPOR guidelines</td><td align="left">Tornado plot</td><td align="left">Distributions</td><td align="left">Only C/E plane</td><td align="left"><p>&#x020ac;22,000/QALY</p><p>&#x020ac;25,000/QALY</p></td></tr><tr><td align="left"><bold>Redondo et al. 2021 </bold>[<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left">No societal perspective</td><td align="left">NRUD</td><td align="left">NA</td><td align="left">Alternative scenario testing a broader definition of influenza complications for hospitalizations and 0% rVE for aTIV vs. SD-TIV. Sensitivity analysis also presented</td><td align="left">NRUD</td><td align="left">Tornado plot</td><td align="left">Distributions</td><td align="left">Acceptability curve and C/E plane</td><td align="left">&#x020ac;30,000/QALY</td></tr><tr><td align="left"><bold>Ruiz Arag&#x000f3;n et al. 2022 </bold>[<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left">NRUD</td><td align="left">NRUD</td><td align="left">NRUD</td><td align="left">Alternative scenario with aQIV vs. HD-QIV rVE based on Coleman et al. 2021.</td><td align="left">Not presented</td><td align="left">Tornado plot</td><td align="left">Not presented</td><td align="left">Only C/E plane</td><td align="left">&#x020ac;25,000/QALY</td></tr><tr><td align="left"><bold>Fochesato et al. 2022 </bold>[<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left">NRUD</td><td align="left">NRUD</td><td align="left">NRUD</td><td align="left">Alternative scenario with rVE from Coleman et al. 2021.</td><td align="left">NRUD</td><td align="left">Tornado plot</td><td align="left">Distributions</td><td align="left">Only C/E plane</td><td align="left">&#x020ac;25,000/QALY</td></tr><tr><td align="left"><bold>Ruiz Arag&#x000f3;n et al. 2023 </bold>[<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left">No NHS perspective, Societal perspective not reported</td><td align="left">Not presented</td><td align="left">NA</td><td align="left">Reverse calculation: rVE for QIVr vs. aQIV calculated after pegging ICER at 25,000&#x020ac;/QALY</td><td align="left">Not presented</td><td align="left">Tornado plot</td><td align="left">Not presented</td><td align="left">Only C/E plane</td><td align="left">&#x020ac;25,000/QALY</td></tr></tbody></table><table-wrap-foot><p><italic>C/E</italic> Cost-effectiveness, <italic>ICER</italic> Incremental cost-effectiveness ratio, <italic>NA</italic> Not applicable, <italic>NHS</italic> National Health System, <italic>NRUD</italic> No relevant uncertainties detected, <italic>QALY</italic>&#x000a0;Quality-adjusted life years</p></table-wrap-foot></table-wrap><table-wrap id="Tab5"><label>Table 5</label><caption><p>Characteristics and analysis of the primary sources of effectiveness data</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><bold>Reference of the effectiveness source</bold></th><th align="left"><bold>Extracted data</bold></th><th align="left"><bold>Type of study</bold></th><th align="left"><bold>Description of the study</bold></th><th align="left"><bold>Summary of analysis with respect to use in EE</bold></th></tr></thead><tbody><tr><td align="left" colspan="5"><bold><italic>Garc&#x000ed;a et al. 2016</italic></bold> [<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td align="left"><bold>Jefferson et al. 2010</bold> [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">VE of the three common influenza strains in the older adults</td><td align="left">Cochrane SLR with MA of VE in 65+ people</td><td align="left">Mainly non-randomized studies. Heterogeneity between studies was low (I<sup>2</sup>&#x0003c;30%). However, risk of bias was evaluated as moderate-to-high, therefore, authors deemed results to be inconclusive.</td><td align="left">While the quality of the individual studies appears insufficient, the body of evidence may be adequate for the purpose pursued in the CEA; in fact, the value used is applied to both comparators.</td></tr><tr><td align="left"><bold>Tricco et al. 2013</bold>[<xref ref-type="bibr" rid="CR23">23</xref>]</td><td align="left">VE non-matching B strain for QIV = TIV VE in complete match</td><td align="left">SLR with MA</td><td align="left">MA of 34 RCTs, including 49 seasons and 94,821 participants. Moderate heterogeneity (I<sup>2</sup>&#x0003c;50%) between studies; RR of various individual studies crossing the 1 line, thus yielding inconclusive MA results.</td><td align="left">The non-matching value is proportionally applied in the CEA according to the degree of B-matching. which is averaged over 9 seasons. Thus, taken altogether the rVE estimation may be adequate.</td></tr><tr><td align="left" colspan="5"><bold><italic>Cr&#x000e9;pey et al. 2020</italic></bold> [<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td align="left"><bold>Diaz Granados et al. 2012</bold>[<xref ref-type="bibr" rid="CR60">60</xref>]</td><td align="left" rowspan="2">TIV VE and additional B strain VE for each age group</td><td align="left">SLR with MA</td><td align="left">MA of 30 RCTs in children and young adults, including 26 seasons and 88,468 participants. Most studies had low risk of bias; however, one sixth of them were low quality. Heterogeneity was moderate for children (I<sup>2</sup>=57%) and low for young adults (I<sup>2</sup>=14%)</td><td align="left">This source seems adequate for younger age groups in the model</td></tr><tr><td align="left"><bold>Centre for Disease Control</bold></td><td align="left">Not specified</td><td align="left">Not specified, original source not cited and unavailable</td><td align="left">Cannot be evaluated. However, input values for the model are transparently presented in the CEA</td></tr><tr><td align="left" colspan="5"><bold><italic>Ruiz Arag&#x000f3;n et al. 2020</italic></bold>[<xref ref-type="bibr" rid="CR32">32</xref>]</td></tr><tr><td align="left"><bold>Belongia et al. 2021</bold> [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="left"><p>VE of QIVe for A/H1N1 and B = QIVc</p><p>QIVe VE against the A/H3N2 strain</p></td><td align="left">SLR with MA</td><td align="left">MA of 56 RW studies of VE with test-negative design and lab-confirmed influenza.</td><td align="left">Test-negative design is only one of the available designs for evaluating VE; thus, not all available evidence is included</td></tr><tr><td align="left"><bold>Boikos et al. 2019</bold> [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td align="left">rVE QIVe vs. QIVc against strain A/H3N2</td><td align="left">RW study</td><td align="left">RW single-season study (2017-18) of ILI cases</td><td align="left">Could not be evaluated because it is an oral communication not publicly available. Other available studies could have been used; however, the reason for this source choice is not given</td></tr><tr><td align="left" colspan="5"><bold><italic>Redondo et al. 2021</italic></bold> [<xref ref-type="bibr" rid="CR35">35</xref>]</td></tr><tr><td align="left"><bold>Govaert et al. 1994</bold> [<xref ref-type="bibr" rid="CR61">61</xref>]</td><td align="left">VE for SD-TIV</td><td align="left">RCT</td><td align="left">RCT of SD-TIV vs. no vaccination in individuals aged 60+ (<italic>n</italic>=1838)</td><td align="left">Robust though rather old study; no studies have been published more recently with the same quality</td></tr><tr><td align="left"><bold>Diaz Granados et al. 2014</bold> [<xref ref-type="bibr" rid="CR22">22</xref>]</td><td align="left">rVE HD-QIV vs. SD-QIV - infection</td><td align="left">RCT</td><td align="left">RCT of HD-TIV vs. SD-TIV in individuals aged 65+ (<italic>n</italic>=31,989). Two seasons (2010-11 y 2011-12)</td><td align="left">Robust RCT. Its results were assumed to be applicable to HD-QIV vs. SD-QIV based on an immune-bridging clinical trial supported by EMA</td></tr><tr><td align="left"><bold>Lee et al. 2018</bold> [<xref ref-type="bibr" rid="CR62">62</xref>]</td><td align="left">rVE HD-QIV vs. SD-QIV -hospitalization</td><td align="left">SLR with MA</td><td align="left">MA of 7 RCTs and RW studies of HD-TIV vs. SD-TIV hospitalizations due to ILI in people 65+. No relevant risk of bias, moderate heterogeneity.</td><td align="left">Another study was published later with similar inclusion criteria and different results.</td></tr><tr><td align="left"><bold>Puig-Barber&#x000e1; et al. 2016</bold> [<xref ref-type="bibr" rid="CR63">63</xref>]</td><td align="left">rVE aTIV vs. SD-TIV</td><td align="left">RW study</td><td align="left">RW single-season study for rVE against hospitalization of virosomal-TIV vs. aTIV in Spanish population of 65+, mainly including lab-confirmed influenza</td><td align="left">Virosomal-TIV was used as an approximation for SD-TIV because despite its supposedly higher immunogenicity, there is no evidence of it being more effective than SD-TIV in preventing influenza hospitalization</td></tr><tr><td align="left" colspan="5"><bold><italic>Ruiz Arag&#x000f3;n et al. 2022</italic></bold> [<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td align="left"><bold><italic>Not available</italic></bold></td><td align="left">VE for QIV</td><td align="left">NA</td><td align="left">NA</td><td align="left">Although mentioned in the methods, no value nor citation are available for QIV absolute effectiveness</td></tr><tr><td align="left"><bold>Diaz Granados et al. 2014</bold> [<xref ref-type="bibr" rid="CR22">22</xref>]</td><td align="left">rVE for HD-QIV vs. SD-QIV</td><td align="left">RCT</td><td align="left">RCT for HD-TIV vs. SD-TIV in people 65+ (<italic>n</italic>=31,989). Two seasons (2010-11 y 2011-12)</td><td align="left">Robust RCT. Its results were assumed to be applicable to HD-QIV vs. SD-QIV based on an immune-bridging clinical trial as supported by EMA</td></tr><tr><td align="left"><bold><italic>Ad-hocx MA</italic></bold> [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left">rVE for aQIV vs. HD-QIV</td><td align="left">MA</td><td align="left">Non-statistically significant MA of 7 RW studies with very high heterogeneity</td><td align="left">The MA was not based on an SLR</td></tr><tr><td align="left" colspan="5"><bold><italic>Fochesato et al. 2022</italic></bold> [<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left"><bold>Belongia et al. 2021</bold>&#x000a0;[<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="left">VE for QIVe</td><td align="left">SRL with MA</td><td align="left">MA of 56 RW studies of VE with test-negative design and lab-confirmed influenza.</td><td align="left">Test-negative design is only one of the available designs for evaluating VE; thus, not all available evidence is included here.</td></tr><tr><td align="left"><bold>Calabr&#x000f3; et al. 2021</bold>&#x000a0;[<xref ref-type="bibr" rid="CR25">25</xref>]</td><td align="left">rVE for aQIV vs. QIVe</td><td align="left">SRL with MA for HTA</td><td align="left">RSL with MA of aTIV vs. TIV.</td><td align="left"/></tr><tr><td align="left" colspan="5"><bold><italic>Ruiz Arag&#x000f3;n et al. 2023</italic></bold> [<xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr><td align="left"><bold>Izurieta et al. 2021</bold> [<xref ref-type="bibr" rid="CR64">64</xref>]</td><td align="left">rVE for QIVr vs. aQIV</td><td align="left">RW study</td><td align="left">RW study of the rVE of QIVr vs. aTIV in people 65+ (Medicare) in a single season (2019-20)</td><td align="left">Season was truncated due to escalation of the COVID-19 pandemic</td></tr></tbody></table><table-wrap-foot><p><italic>aTIV</italic> Adjuvated-TIV, <italic>CDC</italic> Centre for Disease Control, <italic>CEA</italic> Cost-effectiveness analysis, <italic>EMA</italic> European Medicines Agency, <italic>GP</italic> General practice, <italic>ED</italic> Emergency department, <italic>HD-QIV</italic> High-dose-QIV, <italic>HTA</italic> Health-technology assessment, <italic>ILI</italic> Influenza-like illness, <italic>MA</italic> Meta-analysis, <italic>RCT</italic> Randomized controlled study, <italic>rVE</italic> Relative vaccine effectiveness, <italic>RW</italic> Real World, <italic>QIV</italic> Quadrivalent inactivated vaccine, <italic>QIVc</italic> cell-based-QIV, <italic>QIVe</italic> egg-based-QIV, <italic>QIVr</italic> recombinant-QIV, <italic>SD-TIV</italic> Standard-dose-TIV, <italic>SLR</italic> Systematic literature review, <italic>TIV</italic> Trivalent inactivated vaccine, <italic>VE</italic>&#x000a0;Vaccine effectiveness</p></table-wrap-foot></table-wrap></p><sec id="Sec13"><title>Model uncertainty</title><p id="Par52">WHO guidelines [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR28">28</xref>] state that decision trees are appropriate to model short-term outcomes over one influenza season when the intervention is aimed at a population in whom vaccination is unlikely to change the infection dynamics (e.g. older adults). For populations that play a key role in infection transmission (e.g., children), dynamic models should be used. According to these recommendations, all studies included in our analysis used an appropriate model type. Specifically, two studies that include children in their target population used dynamic transmission models [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] to account for <italic>herd immunity</italic>, and one used a static transition model [<xref ref-type="bibr" rid="CR31">31</xref>]. The remaining studies used decision trees [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>], which are appropriate considering the short-term time horizon used for the calculations (one influenza season or 1 year) and the exclusion of the paediatric population from their models. Health outcomes in the decision tree model are defined with sufficient clarity to include all the consequences of influenza infection (symptomatic cases, general practice visits, emergency department visits, inpatient stays and deaths).</p></sec><sec id="Sec14"><title>Methodological uncertainty</title><p id="Par53">All the models studied adequately define population, intervention, comparator, outcomes, and time horizon. Although, these aspects were chosen in accordance with the international [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>] and national [<xref ref-type="bibr" rid="CR40">40</xref>] guidelines on economic evaluations, some merit additional consideration. Population was correctly defined based on the Spanish guidelines for influenza vaccination, which recommend vaccinating high-risk individuals of all ages and the older adults [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], while three articles only considered older adults [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>] which was consistent with the investigational question.</p><p id="Par54">In CEEs, it is essential to clearly define the perspective of the analysis according to guidelines [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], and to report the results separately in order to quantify the costs assumed by each payer. While most studies adopted the societal perspective [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], this approach may not be particularly relevant to the decision-maker when the intervention is aimed at the aging (retired) population. In this regard, five studies [<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR34">34</xref>] used both the Spanish NHS and societal perspectives, one [<xref ref-type="bibr" rid="CR35">35</xref>] chose to only use the Spanish NHS perspective, and another does not explain the perspective adopted, although it is reasonable to assume that they adopted the societal perspective because they include loss of productivity; however, not even this specific topic is clarified, and the NHS and societal perspective results are not presented separately [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par55">All included CEAs estimated the health benefits in terms of quality-adjusted life years (QALYs) as it is the priority outcome for reimbursement negotiations in Spain [<xref ref-type="bibr" rid="CR41">41</xref>]; however, a few have also estimated them in life-years gained (LYG), as well as including a budget-impact model.</p><p id="Par56">Finally, although the WHO recommends [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR28">28</xref>] the inclusion of adverse event after immunization (AEFI) rates in influenza vaccine modelling when possible, none of the analysed studies have done so.</p></sec><sec id="Sec15"><title>Parameter uncertainty</title><p id="Par57">The systematic reviews with meta-analyses published so far have been used as sources for absolute vaccine effectiveness (VE) data (<italic>n</italic>&#x02009;=&#x02009;5, of which one was a Cochrane review [<xref ref-type="bibr" rid="CR42">42</xref>]). Interestingly, to inform relative effectiveness of comparators, one study [<xref ref-type="bibr" rid="CR34">34</xref>] used an ad-hoc meta-analysis that was not based on a systematic search, while another study [<xref ref-type="bibr" rid="CR30">30</xref>] used the result of a meta-analysis that had been measured in the framework of an Italian health-technology assessment and sponsored by the manufacturer [<xref ref-type="bibr" rid="CR25">25</xref>]. In addition, two randomized-controlled trials (RCTs) and three observational studies used only single-season data.</p><p id="Par58">Another key feature to take into consideration when reviewing effectiveness sources is the definition of influenza. While the most reliable way to diagnose influenza infection is laboratory confirmation using a previously established clinical definition, most studies have used the wider, less precise definition of influenza-like illness (ILI), thereby increasing the uncertainty of effectiveness data. Furthermore, two studies do not inform the influenza definition [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]; another one [<xref ref-type="bibr" rid="CR29">29</xref>] used only laboratory-confirmed influenza data, and the other four studies [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR35">35</xref>] describe sources that used either definition (see Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par59">The WHO guidance [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR28">28</xref>] recommends averaging the burden of illness over at least 5 influenza seasons in order to minimize inter-seasonal variability of disease burden, and all CEAs used local epidemiological data. Nonetheless, three CEAs [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>] used only three seasons, one used 1 season for general practice (GP, ) emergency department (ED), and hospitalization, and 6 seasons for deaths [<xref ref-type="bibr" rid="CR31">31</xref>], and one does not specify the period studied [<xref ref-type="bibr" rid="CR30">30</xref>]. Conversely, Cr&#x000e9;pey et al. 2021 [<xref ref-type="bibr" rid="CR29">29</xref>] used five seasons and Redondo et al. 2021 [<xref ref-type="bibr" rid="CR35">35</xref>] used eight, in compliance with best practices.</p><p id="Par60">In cost-utility analyses, utilities are the final outcome that measures the effectiveness of the interventions analysed. All analysed studies use a Spanish study [<xref ref-type="bibr" rid="CR43">43</xref>] to derive disutility associated with influenza, except for one [<xref ref-type="bibr" rid="CR30">30</xref>], which uses Italian data.</p></sec><sec id="Sec16"><title>Management of uncertainty</title><p id="Par61">Deterministic one-way and probabilistic sensitivity analyses (DSA and PSA) were performed in all CEAs. Four [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>] studies did not fully report DSA variation intervals and/or PSA probability distributions. One study [<xref ref-type="bibr" rid="CR32">32</xref>] used an arbitrarily chosen percentage variation of the baseline case value instead of using the measures of dispersion (e.g., confidence intervals) originally estimated from the model.</p></sec></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par62">To our knowledge, this is the first, comprehensive, systematic analysis of all available evidence on the CEAs of influenza vaccines in the population aged&#x02009;&#x02265;&#x02009;60 years in Spain. We used a systematic approach based on various different validated assessment tools to capture the magnitude of the uncertainty of the results [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par63">Our assessment showed that the CEAs published so far generally follow applicable guidelines [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Nonetheless, we found that some decisions concerning the model structure, methods, and parameters of the models did not follow best practices. The derived uncontrolled uncertainty can thus yield non-convergent results that may hinder the decision-making process by adding confounding bias.</p><p id="Par64">Effectiveness is one of the variables with the highest impact on the incremental cost-effectiveness ratio (ICER). VE is hard to determine, mainly due to the seasonal variation of circulating strains and the degree to which the vaccine formulated for each season matches the circulating virus strains in a specific territory. For this reason, the WHO recommends [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR42">42</xref>] deriving VE from systematic reviews with meta-analyses, or using a range of values from RCTs and real-world studies that have undergone sensitivity analyses representative of extreme circumstances [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par65">Very few RCTs in influenza vaccines for the elderly have been published in the past thirty years, although numerous observational studies are published annually [<xref ref-type="bibr" rid="CR47">47</xref>]. Due to the high heterogeneity of study design, it is essential to carefully select the source of efficacy data. The reliability of cost-effectiveness evaluation (CEE) results hinges on the meticulous choice of effectiveness data. According to ISPOR guidelines, modelers should &#x0201c;seek to identify and incorporate all relevant evidence, rather than cherry picking the best single source of evidence for that parameter; use best practice methods to avoid potential biases in parameter estimates that might arise (for example, when estimating treatment effectiveness from observational sources); and employ formal evidence syntheses techniques (meta-analysis and network meta-analysis) as appropriate&#x0201d;.</p><p id="Par66">Nonetheless, we have found that some studies are not transparent in their selection of VE data, and this casts doubts on their results. For example, in Ruiz-Arag&#x000f3;n et al. 2020 [<xref ref-type="bibr" rid="CR32">32</xref>] the reported source [<xref ref-type="bibr" rid="CR27">27</xref>] of rVE data used to compare QIVc vs. QIVe was a presentation for an oral communication in a course that was not accessible [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. The authors do not explain or justify their reason for choosing this source and, as noted by Alvarez et al. 2021 [<xref ref-type="bibr" rid="CR48">48</xref>], at least four other studies had been published at the time of the evaluation [<xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>]. The use of single-season observational studies as a source of rVE data may be unavoidable due to the scarcity of more robust evidence. However, their use should be justified and put in the context of other available evidence. For example, the rVE of aTIV vs. SD-TIV in Redondo et al. 2021 [<xref ref-type="bibr" rid="CR35">35</xref>] is derived from a Spanish single-season study, and the use of this source is thoroughly justified and contextualised in the methods section of the paper.</p><p id="Par67">Deciding whether effectiveness results are correctly used in CEAs may be challenging for the average reader. For example, in Ruiz-Aragon et al. 2022, an ad-hoc meta-analysis was used to estimate the rVE of aQIV vs. HD-QIV. However, article compilation and review methodology are poorly described: half of the included studies were derived from a previous meta-analysis [<xref ref-type="bibr" rid="CR26">26</xref>], and the other half were identified using a &#x0201c;targeted&#x0201d; non-systematic literature review. The estimated rVE of aTIV and HD-TIV was 4.0 (&#x02212;0.05; 8.4), with considerable (<italic>I</italic><sup><italic>2</italic></sup> = 92%) heterogeneity (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.1) [<xref ref-type="bibr" rid="CR12">12</xref>]. While the authors conclude that aTIV and HD-TIV, and therefore aQIV and HD-QIV, are equally effective, no firm conclusions can be drawn due to the high degree of heterogeneity. Thus, the source of this heterogeneity should be investigated to assess whether it makes sense to combine studies, and a series of strategies, such as subgroup meta-analysis, can be used to reduce heterogeneity [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. For example, studies including GP outcomes could have been separated from those not including GP. However, the authors decided to use a random-effect method to meta-analyse the entire data set incorporating the &#x0201c;noise&#x0201d; from heterogeneity, but this did not compensate for the fact that different outcomes were included in the same average [<xref ref-type="bibr" rid="CR53">53</xref>], and the results of the meta-analysis do not support any firm conclusions. In this respect, according to the ECDC [<xref ref-type="bibr" rid="CR54">54</xref>], there is limited evidence of the higher effectiveness of adjuvated vaccines compared to standard doses against laboratory-confirmed influenza with rVE vs. SD ranging between &#x02212;&#x02009;30% (95%CI: &#x02212;146 to 31%) and 88% (95%CI: 51 to 100) based on seven non-randomized studies of intervention (low certainty of evidence) [<xref ref-type="bibr" rid="CR54">54</xref>]. Domnich et al. 2017 [<xref ref-type="bibr" rid="CR55">55</xref>], attempting to synthesize the available efficacy data for aTIV, acknowledged that it was impossible to determine the rVE of aTIV vs. other vaccines due to the different designs, settings, comparators, and outcomes used in the studies analysed. Finally, in their RCT assessing aQIV efficacy vs. a non-influenza comparator, Beran et al. 2021 [<xref ref-type="bibr" rid="CR56">56</xref>] were unable to meet their pre-specified primary efficacy endpoint. RCTs support the greater efficacy of high-dose vs. standard-dose vaccines in the elderly, and in observational studies they are generally more effective than standard-dose vaccines. Thus, according to the ECDC [<xref ref-type="bibr" rid="CR54">54</xref>], the rVE estimate against laboratory-confirmed influenza was 24.2% (95%CI: 9.7 to 36.5%) in one RCT (moderate certainty of evidence).</p><p id="Par68">Similar reasoning applies to studies [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] using data from Coleman et al. 2021 [<xref ref-type="bibr" rid="CR26">26</xref>], in which at least three of the included studies have a high risk of bias, and the resulting meta-analysis is highly heterogenous. As pointed out by Yin et al. 2021 [<xref ref-type="bibr" rid="CR57">57</xref>], the combination of these factors &#x0201c;detracts from the value of Coleman&#x02019;s analysis to inform clinical practice and policy recommendations&#x0201d; [<xref ref-type="bibr" rid="CR30">30</xref>]. In summary, working with meta-analyses results requires careful assessment of the meta-analyses themselves in order to prevent introducing uncertainty and structural bias in the model.</p><p id="Par69">In summary, when considering effectiveness data in a CEA, decision-makers should retrieve original data sources and critically consider the general study design, how influenza cases were defined, how many seasons did it include, if it was a meta-analysis, how high was heterogeneity between studies? Were the summary measures correctly derived and interpreted? Was the selected source the best available in general?</p><p id="Par70">Fochesato et al. [<xref ref-type="bibr" rid="CR30">30</xref>] compare aQIV to QIVe, not including other relevant comparators, such as HD-QIV. According to the authors, aQIV has already been shown to be more cost-effective than HD-QIV in the older adults in Spain [<xref ref-type="bibr" rid="CR34">34</xref>].&#x000a0;However, Redondo et al. 2021 [<xref ref-type="bibr" rid="CR35">35</xref>] had shown that HD-QIV is cost-effective compared to aQIV from the NHS perspective. This discrepancy in the evidence is not discussed by Fochesato et al. 2022, and HD-QIV and other potential comparators were not included in their model. Thus, as new vaccine options become available, multiple comparators may be important for decision-making, especially when previous studies have reported contradictory results. Therefore, comparator selection should be clearly justified [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR38">38</xref>].</p><p id="Par71">The WHO guidelines recommend estimating burden of illness by averaging at least 5 seasons. Although the Spanish Influenza Surveillance System provides data for as many seasons as desired, only two CEAs [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR35">35</xref>] have averaged 5 seasons. It is reasonable to assume that the more seasons used, the more robust the estimated burden-of-illness.</p><p id="Par72">In dynamic models, the modelling of contact maps and rates is crucial. In Fochesato et al. 2022, Italian data were used due to the lack of Spanish data. The Italian data were considered transferable to Spanish models when at least one of the viral strains was circulating in both Italy and Spain in the same season. However, the coinciding strain is often H1N1, against which all vaccines are highly effective in the elderly [<xref ref-type="bibr" rid="CR58">58</xref>], while in four seasons either H3N2 or B (or both) were present in one of the two countries and absent in the other. Thus, Italian data cannot be transferred to the Spanish model. Furthermore, since model calibration was not reported, it is impossible to determine the extent to which Italian data reproduce Spanish epidemiology.</p><p id="Par73">According to specific guidelines, adverse events (AE) should be included in economic models of influenza vaccines [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], but none of the analysed CEAs has done so, and none have explained this omission, although it is probably due to the generally perceived good safety profile of influenza vaccines and the difficulty in estimating the cost of such adverse events in Spain. From a 2021 systematic review [<xref ref-type="bibr" rid="CR59">59</xref>] that gathered and analysed the inclusion of safety-related issues in economic evaluations for seasonal influenza vaccine, it emerges that, over the included 52 economic evaluations, the consequences of AEFIs were included as: direct and indirect costs in 90% and 27% of cases, an disutilities in 37% of them. Severe AEFI (GBS, anaphylaxis, and MSW) were included in 33% of studies, minor/mild AEFI (local and systemic) in 46%, and 40% of studies did not specify the considered type of AEFI.</p><p id="Par74">To sum up, apart from the typical aspects of a CEA (perspective, time-horizon, discounting, etc.) decision-makers should pay attention to such parameters as the number of influenza seasons used to estimate disease burden, the transferability of parameters derived from other settings, the accounting for adverse events both in terms of cost and disutility,</p><p id="Par75">Finally, sensitivity and scenario analyses are key features of parameter uncertainty. This particularly affects the reader&#x02019;s evaluation of the impact of parameters showing significant uncertainty.</p><p id="Par76">Thus, a lack of proper uncertainty management as well as insufficient transparency in presenting and justifying design and parameter choice should alert the critical reader and warrant a deeper investigation of the quality of the CEA.</p><p id="Par77">This study has limitations inherent to its design. First, a certain degree of subjectiveness is unavoidable. To overcome this, the study was performed by a multidisciplinary team made up of clinicians from all therapeutic areas involved in influenza prevention, as well as experts in the field of pharmacoeconomics. Second, there are no &#x0201c;rules&#x0201d; that can be applied to show whether a study has been well conducted and to rate the seriousness of deviations from published recommendations. Although we used TRUST to analyse the relevant CEAs, this tool is not straightforward. To overcome this, we reviewed the applicable recommendations of official organizations such as ISPOR, WHO and national institutions, and constructed a common theoretical framework that all researchers involved could use to perform an objective, comprehensive, critical analysis. The primary aim of this analysis was to provide a descriptive overview of the current landscape of CEAs for influenza vaccines in the elderly population in Spain. Based on the insights gained from this review, we are in the process of developing a practical guide for decision-makers. This guide, which will be available soon, is designed to help readers independently identify and assess uncertainties in influenza CEAs, enabling more informed decision-making.</p></sec><sec id="Sec18"><title>Conclusion</title><p id="Par78">A number of CEAs assessing the cost-effectiveness of influenza vaccines have been published in recent years. To properly leverage the result of these studies, we must never forget that we deal with estimates deriving from modelling techniques. Thus, due to the challenges inherent to modelling, uncertainty management is crucial, particularly when analysing variables such as effectiveness. Justifying the selection of primary clinical data sources and openly discussing their limitations is essential for reader interpretation. However, healthcare professionals and decision-makers should be aware that &#x0201c;all that glitters is not gold&#x0201d; in economic evaluations, and transparent, comprehensive information on methods and results, together with careful critical reading, are paramount in evidence-based medicine.</p></sec><sec id="Sec19" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12879_2025_10442_MOESM1_ESM.docx"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material></p><p>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12879_2025_10442_MOESM2_ESM.docx"><caption><p>Supplementary Material 2.</p></caption></media></supplementary-material></p><p>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12879_2025_10442_MOESM3_ESM.docx"><caption><p>Supplementary Material 3.</p></caption></media></supplementary-material></p><p>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="12879_2025_10442_MOESM4_ESM.docx"><caption><p>Supplementary Material 4.</p></caption></media></supplementary-material></p><p>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="12879_2025_10442_MOESM5_ESM.pdf"><caption><p>Supplementary Material 5.</p></caption></media></supplementary-material></p><p>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="12879_2025_10442_MOESM6_ESM.pdf"><caption><p>Supplementary Material 6.</p></caption></media></supplementary-material></p><p>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="12879_2025_10442_MOESM7_ESM.pdf"><caption><p>Supplementary Material 7.</p></caption></media></supplementary-material></p><p>
<supplementary-material content-type="local-data" id="MOESM8"><media xlink:href="12879_2025_10442_MOESM8_ESM.pdf"><caption><p>Supplementary Material 8.</p></caption></media></supplementary-material></p><p>
<supplementary-material content-type="local-data" id="MOESM9"><media xlink:href="12879_2025_10442_MOESM9_ESM.pdf"><caption><p>Supplementary Material 9.</p></caption></media></supplementary-material></p><p>
<supplementary-material content-type="local-data" id="MOESM10"><media xlink:href="12879_2025_10442_MOESM10_ESM.pdf"><caption><p>Supplementary Material 10.</p></caption></media></supplementary-material></p><p>
<supplementary-material content-type="local-data" id="MOESM11"><media xlink:href="12879_2025_10442_MOESM11_ESM.pdf"><caption><p>Supplementary Material 11.</p></caption></media></supplementary-material></p><p>
<supplementary-material content-type="local-data" id="MOESM12"><media xlink:href="12879_2025_10442_MOESM12_ESM.pdf"><caption><p>Supplementary Material 12.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AMSTAR-2</term><def><p id="Par5">A Measurement Tool to Assess Systematic Reviews-2</p></def></def-item><def-item><term>aQIV</term><def><p id="Par6">adjuvated-Quadrivalent Influenza Vaccine</p></def></def-item><def-item><term>aTIV</term><def><p id="Par7">adjuvated Trivalent Influenza Vaccine</p></def></def-item><def-item><term>CEA</term><def><p id="Par8">Cost-Effectiveness Analysis</p></def></def-item><def-item><term>CEE</term><def><p id="Par9">Complete Economic Evaluation</p></def></def-item><def-item><term>DSA</term><def><p id="Par10">Deterministic Sensitivity Analysis</p></def></def-item><def-item><term>ED</term><def><p id="Par11">Emergency Department</p></def></def-item><def-item><term>GP</term><def><p id="Par12">General Practice</p></def></def-item><def-item><term>HD-QIV</term><def><p id="Par13">High-Dose Quadrivalent Influenza Vaccine</p></def></def-item><def-item><term>NHS</term><def><p id="Par14">National Health Service</p></def></def-item><def-item><term>ICER</term><def><p id="Par15">Incremental Cost-Effectiveness Ratio</p></def></def-item><def-item><term>NOS</term><def><p id="Par16">Newcastle-Ottawa Scale</p></def></def-item><def-item><term>PRISMA</term><def><p id="Par17">Preferred Reporting Items for Systematic Review and Meta-Analysis</p></def></def-item><def-item><term>PSA</term><def><p id="Par18">Probabilistic Sensitivity Analysis</p></def></def-item><def-item><term>QIV</term><def><p id="Par19">Quadrivalent Influenza Vaccine</p></def></def-item><def-item><term>QIVe</term><def><p id="Par20">egg-based Quadrivalent Influenza Vaccine</p></def></def-item><def-item><term>QIVc</term><def><p id="Par21">cell-based Quadrivalent Influenza Vaccine</p></def></def-item><def-item><term>QIVr</term><def><p id="Par22">Recombinant Quadrivalent Influenza Vaccine</p></def></def-item><def-item><term>RCT</term><def><p id="Par23">Randomized-Controlled Trial</p></def></def-item><def-item><term>RoB 2</term><def><p id="Par24">Risk of bias 2</p></def></def-item><def-item><term>rVE</term><def><p id="Par25">relative Vaccine Effectiveness</p></def></def-item><def-item><term>SD-QIV</term><def><p id="Par26">Standard-Dose Quadrivalent Influenza Vaccine</p></def></def-item><def-item><term>TIV</term><def><p id="Par27">Trivalent Influenza Vaccine</p></def></def-item><def-item><term>TRUST</term><def><p id="Par28">TRansparent Uncertainty ASsessmenT</p></def></def-item><def-item><term>WHO</term><def><p id="Par29">World Health Organization</p></def></def-item><def-item><term>WTP</term><def><p id="Par30">Willingness-To-Pay</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank Maria Giovanna Ferrario, PhD, Blanca Piedrafita, PhD, Celia Miguel Blanco, PhD, and the whole team at Medical Scientific Consulting, SL (Valencia, Spain) for their support in the development and writing of this study.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>All authors, ROLL, JDD, AGM, FMT, ERM, JLLBC, PIPJ, JMFA, JMAP, contributed to the study conception and design, to the analysis and interpretation of the data, to the drafting of the article and its critical reading for important intellectual content, and approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was funded by Sanofi. Medical writing was provided by Medical Statistics Consulting, SL (Valencia, Spain) and funded by Sanofi.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All study materials are available in the additional files.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par79">Ethics approval does not apply to this study because there are no patients involved.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par80">Not applicable, no personal data have been included in the publication.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par81">ROLL has received fees for academic services and grants to attend international meetings from Abbot, CSL, GSK, Moderna, MSD, Novavax, Pfizer, Roche and Sanofi. JDD reports personal fees/grants from GSK, Sanofi Pasteur and MSD and nonfinancial support from Sanofi Pasteur and MSD. AGM has received grants paid to his institutions by Sanofi, GSK, and Pfizer. He has also received personal consulting fees from Sanofi, MSD, and Moderna, as well as for lectures and congress presentations from GKS, HIPRA, Astra-Zeneca, Novavax, Pfizer and Jannsen. He has received support for attending meetigs/travel by Pfizer, MSD, GSK, and Sanofi. Finally, he declares having participated in safety monitory boards for Pfizer, Hipra and Novavax. ERM has participated in advisory boards, conferences, courses and lectures organized by Glaxo SmithKline, Sanofi Pasteur, MSD, GSK, Seqirus, Pfizer, Moderna, Takeda, and AstraZeneca. She has also participated in data safety or advisory boards from Pfizer, Sanofi, MSD, Moderna, Takeda and GSK. FMT has received honoraria and/or reimbursement for participation fees/travel expenses from GSK, Pfizer Inc, Sanofi Pasteur, MSD, Seqirus, Biofabri, and Janssen for taking part in advisory boards and expert meetings and for acting as a speaker in congresses outside the scope of the submitted work. He has also acted as principal investigator in randomized controlled trials sponsored by the above-mentioned companies as well as by Ablynx, Gilead, Regeneron, Roche, Abbott, Novavax, and MedImmune, with honoraria paid to his institution. JMAP declares having received consulting fees from Sanofi. JLLBC, PIPJ and JMFA are employees of Sanofi and may hold shares and/or stock options in the company.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Organization. Influenza (Seasonal). 2023. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/newsroom/fact-sheets/detail/influenza-(seasonal)#:~:text=In%20temperate%20climates%2C%20seasonal%20epidemics,ranges%20from%201%E2%80%934%20days">https://www.who.int/newsroom/fact-sheets/detail/influenza-(seasonal)#:~:text=In%20temperate%20climates%2C%20seasonal%20epidemics,ranges%20from%201%E2%80%934%20days</ext-link>.&#x000a0;Accessed Jan 2025.</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;rez-Rubio</surname><given-names>A</given-names></name><name><surname>Platero</surname><given-names>L</given-names></name><name><surname>Eiros Bouza</surname><given-names>JM</given-names></name></person-group><article-title>Seasonal influenza in Spain: clinical and economic burden and vaccination programmes</article-title><source>Med Clin (Barc)</source><year>2019</year><volume>153</volume><issue>1</issue><fpage>16</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.medcli.2018.11.014</pub-id><pub-id pub-id-type="pmid">30621906</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">P&#x000e9;rez-Rubio A, Platero L, Eiros Bouza JM. Seasonal influenza in Spain: clinical and economic burden and vaccination programmes. Med Clin (Barc). 2019;153(1):16&#x02013;27.<pub-id pub-id-type="pmid">30621906</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention. People at higher risk of flu complications. 2023.</mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Langer</surname><given-names>J</given-names></name><name><surname>Welch</surname><given-names>VL</given-names></name><name><surname>Moran</surname><given-names>MM</given-names></name><name><surname>Cane</surname><given-names>A</given-names></name><name><surname>Lopez</surname><given-names>SMC</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><etal/></person-group><article-title>High clinical burden of Influenza disease in adults aged&#x02009;&#x02265;&#x02009;65 years: can we do better? A systematic literature review</article-title><source>Adv Ther</source><year>2023</year><volume>40</volume><issue>4</issue><fpage>1601</fpage><lpage>1627</lpage><pub-id pub-id-type="doi">10.1007/s12325-023-02432-1</pub-id><pub-id pub-id-type="pmid">36790682</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Langer J, Welch VL, Moran MM, Cane A, Lopez SMC, Srivastava A, et al. High clinical burden of Influenza disease in adults aged&#x02009;&#x02265;&#x02009;65 years: can we do better? A systematic literature review. Adv Ther. 2023;40(4):1601&#x02013;27.<pub-id pub-id-type="pmid">36790682</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Vaccines against influenza: WHO position paper&#x02013;may 2022&#x02013;</article-title><source>Wkly Epidemiol Rec</source><year>2022</year><volume>97</volume><issue>19</issue><fpage>185</fpage><lpage>208</lpage></element-citation><mixed-citation id="mc-CR5" publication-type="journal">World Health Organization. Vaccines against influenza: WHO position paper&#x02013;may 2022&#x02013;. Wkly Epidemiol Rec. 2022;97(19):185&#x02013;208.</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Sistema Nacional de Salud. Calendario com&#x000fa;n de vacunaci&#x000f3;n a lo largo de toda la vida. Calendario recomendado a&#x000f1;o 2023 2022. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario-y-coberturas/docs/CalendarioVacunacion_Todalavida.pdf">https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario-y-coberturas/docs/CalendarioVacunacion_Todalavida.pdf</ext-link>. </mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Consejo Interterritorial - Sistema Nacional de Salud. Recomendaciones De Vacunaci&#x000f3;n Frente A La Gripe. 2022.</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Osterholm</surname><given-names>MT</given-names></name><name><surname>Kelley</surname><given-names>NS</given-names></name><name><surname>Sommer</surname><given-names>A</given-names></name><name><surname>Belongia</surname><given-names>EA</given-names></name></person-group><article-title>Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis</article-title><source>Lancet Infect Dis</source><year>2012</year><volume>12</volume><issue>1</issue><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(11)70295-X</pub-id><pub-id pub-id-type="pmid">22032844</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36&#x02013;44.<pub-id pub-id-type="pmid">22032844</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Keitel</surname><given-names>WA</given-names></name><name><surname>Atmar</surname><given-names>RL</given-names></name><name><surname>Cate</surname><given-names>TR</given-names></name><name><surname>Petersen</surname><given-names>NJ</given-names></name><name><surname>Greenberg</surname><given-names>SB</given-names></name><name><surname>Ruben</surname><given-names>F</given-names></name><etal/></person-group><article-title>Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons</article-title><source>Arch Intern Med</source><year>2006</year><volume>166</volume><issue>10</issue><fpage>1121</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1001/archinte.166.10.1121</pub-id><pub-id pub-id-type="pmid">16717175</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Keitel WA, Atmar RL, Cate TR, Petersen NJ, Greenberg SB, Ruben F, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006;166(10):1121&#x02013;7.<pub-id pub-id-type="pmid">16717175</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Grupo de Trabajo Criterios 2011 de la Ponencia de Programa y Registro de Vacunaciones. Criterios de evaluaci&#x000f3;n para fundamentar modificaciones en el programa de vacunaci&#x000f3;n en Espa&#x000f1;a. 2011.</mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Brisson</surname><given-names>M</given-names></name><name><surname>Edmunds</surname><given-names>WJ</given-names></name></person-group><article-title>Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs</article-title><source>Med Decis Mak</source><year>2006</year><volume>26</volume><issue>5</issue><fpage>434</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1177/0272989X06290485</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Mak. 2006;26(5):434&#x02013;46.</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="book"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Chandler</surname><given-names>J</given-names></name><name><surname>Cumpston</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Page</surname><given-names>MJ</given-names></name><etal/></person-group><source>Cochrane handbook for systematic reviews of interventions</source><year>2019</year><publisher-name>Wiley</publisher-name></element-citation><mixed-citation id="mc-CR12" publication-type="book">Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. Wiley; 2019.</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Newall</surname><given-names>AT</given-names></name><name><surname>Chaiyakunapruk</surname><given-names>N</given-names></name><name><surname>Lambach</surname><given-names>P</given-names></name><name><surname>Hutubessy</surname><given-names>RCW</given-names></name></person-group><article-title>WHO guidance on the economic evaluation of influenza vaccination</article-title><source>Influenza Other Respir Viruses</source><year>2018</year><volume>12</volume><issue>2</issue><fpage>211</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/irv.12510</pub-id><pub-id pub-id-type="pmid">29024434</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Newall AT, Chaiyakunapruk N, Lambach P, Hutubessy RCW. WHO guidance on the economic evaluation of influenza vaccination. Influenza Other Respir Viruses. 2018;12(2):211&#x02013;9.<pub-id pub-id-type="pmid">29024434</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Grimm</surname><given-names>SE</given-names></name><name><surname>Pouwels</surname><given-names>X</given-names></name><name><surname>Ramaekers</surname><given-names>BLT</given-names></name><name><surname>Wijnen</surname><given-names>B</given-names></name><name><surname>Knies</surname><given-names>S</given-names></name><name><surname>Grutters</surname><given-names>J</given-names></name><etal/></person-group><article-title>Development and validation of the TRansparent uncertainty ASsessmenT (TRUST) Tool for assessing uncertainties in Health Economic decision models</article-title><source>PharmacoEconomics</source><year>2020</year><volume>38</volume><issue>2</issue><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1007/s40273-019-00855-9</pub-id><pub-id pub-id-type="pmid">31709496</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Grimm SE, Pouwels X, Ramaekers BLT, Wijnen B, Knies S, Grutters J, et al. Development and validation of the TRansparent uncertainty ASsessmenT (TRUST) Tool for assessing uncertainties in Health Economic decision models. PharmacoEconomics. 2020;38(2):205&#x02013;16.<pub-id pub-id-type="pmid">31709496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Briggs</surname><given-names>AH</given-names></name></person-group><article-title>Handling uncertainty in cost-effectiveness models</article-title><source>PharmacoEconomics</source><year>2000</year><volume>17</volume><issue>5</issue><fpage>479</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.2165/00019053-200017050-00006</pub-id><pub-id pub-id-type="pmid">10977389</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Briggs AH. Handling uncertainty in cost-effectiveness models. PharmacoEconomics. 2000;17(5):479&#x02013;500.<pub-id pub-id-type="pmid">10977389</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Briggs</surname><given-names>AH</given-names></name><name><surname>Gray</surname><given-names>AM</given-names></name></person-group><article-title>Handling uncertainty when performing economic evaluation of healthcare interventions</article-title><source>Health Technol Assess</source><year>1999</year><volume>3</volume><issue>2</issue><fpage>1</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.3310/hta3020</pub-id><pub-id pub-id-type="pmid">10448202</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess. 1999;3(2):1&#x02013;134.<pub-id pub-id-type="pmid">10448202</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Briggs</surname><given-names>AH</given-names></name><name><surname>Weinstein</surname><given-names>MC</given-names></name><name><surname>Fenwick</surname><given-names>EA</given-names></name><name><surname>Karnon</surname><given-names>J</given-names></name><name><surname>Sculpher</surname><given-names>MJ</given-names></name><name><surname>Paltiel</surname><given-names>AD</given-names></name></person-group><article-title>Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling Good Research practices Task Force Working Group&#x02013;6</article-title><source>Med Decis Making</source><year>2012</year><volume>32</volume><issue>5</issue><fpage>722</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1177/0272989X12458348</pub-id><pub-id pub-id-type="pmid">22990087</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling Good Research practices Task Force Working Group&#x02013;6. Med Decis Making. 2012;32(5):722&#x02013;32.<pub-id pub-id-type="pmid">22990087</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>LL</given-names></name><name><surname>Wang</surname><given-names>YY</given-names></name><name><surname>Yang</surname><given-names>ZH</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Weng</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>XT</given-names></name></person-group><article-title>Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?</article-title><source>Mil Med Res</source><year>2020</year><volume>7</volume><issue>1</issue><fpage>7</fpage><pub-id pub-id-type="pmid">32111253</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7(1):7.<pub-id pub-id-type="pmid">32111253</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Sterne JA, Savovi&#x00107; J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:1&#x02013;8. 10.1136/bmj.l4898.&#x000a0;Published 28 Aug 2019.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Wells G, Shea B, O&#x02019;Connell D, Peterson J, Welch V, Losos M, et al. Newcastle-Ottawa quality assessment scale cohort studies. University of Ottawa. 2014.&#x000a0;<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK99082/bin/appb-fm4.pdf">https://www.ncbi.nlm.nih.gov/books/NBK99082/bin/appb-fm4.pdf</ext-link>.&#x000a0;Last accessed Jan 2025.</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Shea</surname><given-names>BJ</given-names></name><name><surname>Reeves</surname><given-names>BC</given-names></name><name><surname>Wells</surname><given-names>G</given-names></name><name><surname>Thuku</surname><given-names>M</given-names></name><name><surname>Hamel</surname><given-names>C</given-names></name><name><surname>Moran</surname><given-names>J</given-names></name><etal/></person-group><article-title>AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both</article-title><source>BMJ</source><year>2017</year><volume>358</volume><fpage> j4008</fpage><pub-id pub-id-type="doi">10.1136/bmj.j4008</pub-id><pub-id pub-id-type="pmid">28935701</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.<pub-id pub-id-type="pmid">28935701</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>DiazGranados</surname><given-names>CA</given-names></name><name><surname>Dunning</surname><given-names>AJ</given-names></name><name><surname>Kimmel</surname><given-names>M</given-names></name><name><surname>Kirby</surname><given-names>D</given-names></name><name><surname>Treanor</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy of high-dose versus standard-dose influenza vaccine in older adults</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>7</issue><fpage>635</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1315727</pub-id><pub-id pub-id-type="pmid">25119609</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635&#x02013;45.<pub-id pub-id-type="pmid">25119609</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Tricco</surname><given-names>AC</given-names></name><name><surname>Chit</surname><given-names>A</given-names></name><name><surname>Soobiah</surname><given-names>C</given-names></name><name><surname>Hallett</surname><given-names>D</given-names></name><name><surname>Meier</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis</article-title><source>BMC Med</source><year>2013</year><volume>11</volume><fpage>153</fpage><pub-id pub-id-type="doi">10.1186/1741-7015-11-153</pub-id><pub-id pub-id-type="pmid">23800265</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11:153.<pub-id pub-id-type="pmid">23800265</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Belongia</surname><given-names>EA</given-names></name><name><surname>Simpson</surname><given-names>MD</given-names></name><name><surname>King</surname><given-names>JP</given-names></name><name><surname>Sundaram</surname><given-names>ME</given-names></name><name><surname>Kelley</surname><given-names>NS</given-names></name><name><surname>Osterholm</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies</article-title><source>Lancet Infect Dis</source><year>2016</year><volume>16</volume><issue>8</issue><fpage>942</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(16)00129-8</pub-id><pub-id pub-id-type="pmid">27061888</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942&#x02013;51.<pub-id pub-id-type="pmid">27061888</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Calabr&#x000f2;</surname><given-names>GE</given-names></name><name><surname>Boccalini</surname><given-names>S</given-names></name><name><surname>Bonanni</surname><given-names>P</given-names></name><name><surname>Bechini</surname><given-names>A</given-names></name><name><surname>Panatto</surname><given-names>D</given-names></name><name><surname>Lai</surname><given-names>PL</given-names></name></person-group><article-title>Valutazione Di Health Technology Assessment (HTA) Del vaccino antinfluenzale quadrivalente adiuvato: Fluad Tetra</article-title><source>Ital J Public Health</source><year>2021</year><volume>10</volume><fpage>97</fpage><lpage>122</lpage></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Calabr&#x000f2; GE, Boccalini S, Bonanni P, Bechini A, Panatto D, Lai PL. Valutazione Di Health Technology Assessment (HTA) Del vaccino antinfluenzale quadrivalente adiuvato: Fluad Tetra. Ital J Public Health. 2021;10:97&#x02013;122.</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>BL</given-names></name><name><surname>Sanderson</surname><given-names>R</given-names></name><name><surname>Haag</surname><given-names>MDM</given-names></name><name><surname>McGovern</surname><given-names>I</given-names></name></person-group><article-title>Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis</article-title><source>Influenza Other Respir Viruses</source><year>2021</year><volume>15</volume><issue>6</issue><fpage>813</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1111/irv.12871</pub-id><pub-id pub-id-type="pmid">34081398</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Coleman BL, Sanderson R, Haag MDM, McGovern I. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respir Viruses. 2021;15(6):813&#x02013;23.<pub-id pub-id-type="pmid">34081398</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Boikos T, editor Effectiveness of the cell culture- and egg-derived, seasonal influenza vaccine during the 2017&#x02013;2018 Northern hemisphere influenza season. NFID Clinical Vaccinology Course; November 9&#x02013;10, 2018; Bethesda, MD. <ext-link ext-link-type="uri" xlink:href="https://www.izsummitpartners.org/content/uploads/019/05/1-effectiveness-of-cell-culture-and-eggderived-flu-vax-during-2017-2018-fluseason.pdf">https://www.izsummitpartners.org/content/uploads/019/05/1-effectiveness-of-cell-culture-and-eggderived-flu-vax-during-2017-2018-fluseason.pdf</ext-link> .&#x000a0;Accessed Jan 2025.</mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">WHO guide for standardization of economic evaluations of immunization programmes, 2nd edition. Geneva: World Health Organization; 2019. Licence: CC BY-NC SA 3.0 IGO. Available at: <ext-link ext-link-type="uri" xlink:href="https://WHO-IVB-19.10-eng.pdf">WHO-IVB-19.10-eng.pdf</ext-link>.&#x000a0;Accessed Jan 2025.</mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Cr&#x000e9;pey</surname><given-names>P</given-names></name><name><surname>Redondo</surname><given-names>E</given-names></name><name><surname>D&#x000ed;ez-Domingo J,Ortiz de Lejarazu R, Martin&#x000f3;n-Torres F, Gil de Miguel &#x000c1;,</surname><given-names>J</given-names></name><name><surname>Ortiz de Lejarazu</surname><given-names>R</given-names></name><name><surname>Martin&#x000f3;n-Torres</surname><given-names>F</given-names></name><collab>Gil de Miguel &#x000c1;</collab><etal/></person-group><article-title>From trivalent to quadrivalent influenza vaccines: public health and economic burden for different immunization strategies in Spain</article-title><source>PLoS ONE.</source><year>2020</year><volume>15</volume><issue>5</issue><fpage>e0233526</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0233526</pub-id><pub-id pub-id-type="pmid">32437476</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Cr&#x000e9;pey P, Redondo E, D&#x000ed;ez-Domingo J,Ortiz de Lejarazu R, Martin&#x000f3;n-Torres F, Gil de Miguel &#x000c1;, J, Ortiz de Lejarazu R, Martin&#x000f3;n-Torres F, Gil de Miguel &#x000c1;, et al. From trivalent to quadrivalent influenza vaccines: public health and economic burden for different immunization strategies in Spain. PLoS ONE. 2020;15(5):e0233526.<pub-id pub-id-type="pmid">32437476</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Fochesato</surname><given-names>A</given-names></name><name><surname>Sottile</surname><given-names>S</given-names></name><name><surname>Pugliese</surname><given-names>A</given-names></name><name><surname>M&#x000e1;rquez-Pel&#x000e1;ez</surname><given-names>S</given-names></name><name><surname>Toro-Diaz</surname><given-names>H</given-names></name><name><surname>Gani</surname><given-names>R</given-names></name><etal/></person-group><article-title>An economic evaluation of the adjuvanted quadrivalent influenza vaccine compared with standard-dose quadrivalent influenza vaccine in the Spanish older adult population</article-title><source>Vaccines (Basel)</source><year>2022</year><volume>10</volume><issue>8</issue><fpage>1360</fpage><pub-id pub-id-type="doi">10.3390/vaccines10081360</pub-id><pub-id pub-id-type="pmid">36016247</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Fochesato A, Sottile S, Pugliese A, M&#x000e1;rquez-Pel&#x000e1;ez S, Toro-Diaz H, Gani R, et al. An economic evaluation of the adjuvanted quadrivalent influenza vaccine compared with standard-dose quadrivalent influenza vaccine in the Spanish older adult population. Vaccines (Basel). 2022;10(8):1360.<pub-id pub-id-type="pmid">36016247</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a</surname><given-names>A</given-names></name><name><surname>Ortiz de Lejarazu</surname><given-names>R</given-names></name><name><surname>Reina</surname><given-names>J</given-names></name><name><surname>Callejo</surname><given-names>D</given-names></name><name><surname>Cuervo</surname><given-names>J</given-names></name><name><surname>Morano Larragueta</surname><given-names>R</given-names></name></person-group><article-title>Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain</article-title><source>Hum Vaccin Immunother</source><year>2016</year><volume>12</volume><issue>9</issue><fpage>2269</fpage><lpage>2277</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1182275</pub-id><pub-id pub-id-type="pmid">27184622</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Garc&#x000ed;a A, Ortiz de Lejarazu R, Reina J, Callejo D, Cuervo J, Morano Larragueta R. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain. Hum Vaccin Immunother. 2016;12(9):2269&#x02013;77.<pub-id pub-id-type="pmid">27184622</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Arag&#x000f3;n</surname><given-names>J</given-names></name><name><surname>Gani</surname><given-names>R</given-names></name><name><surname>M&#x000e1;rquez</surname><given-names>S</given-names></name><name><surname>Alvarez</surname><given-names>P</given-names></name></person-group><article-title>Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain</article-title><source>Hum Vaccin Immunother</source><year>2020</year><volume>16</volume><issue>9</issue><fpage>2238</fpage><lpage>2244</lpage><pub-id pub-id-type="doi">10.1080/21645515.2020.1712935</pub-id><pub-id pub-id-type="pmid">32040379</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Ruiz-Arag&#x000f3;n J, Gani R, M&#x000e1;rquez S, Alvarez P. Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain. Hum Vaccin Immunother. 2020;16(9):2238&#x02013;44.<pub-id pub-id-type="pmid">32040379</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Arag&#x000f3;n</surname><given-names>J</given-names></name><name><surname>M&#x000e1;rquez-Pel&#x000e1;ez</surname><given-names>S</given-names></name></person-group><article-title>An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain</article-title><source>Vaccines (Basel)</source><year>2023</year><volume>11</volume><issue>2</issue><fpage>427</fpage><pub-id pub-id-type="doi">10.3390/vaccines11020427</pub-id><pub-id pub-id-type="pmid">36851304</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Ruiz-Arag&#x000f3;n J, M&#x000e1;rquez-Pel&#x000e1;ez S. An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain. Vaccines (Basel). 2023;11(2):427.<pub-id pub-id-type="pmid">36851304</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Arag&#x000f3;n</surname><given-names>J</given-names></name><name><surname>M&#x000e1;rquez-Pel&#x000e1;ez</surname><given-names>S</given-names></name><name><surname>Gani</surname><given-names>R</given-names></name><name><surname>Alvarez</surname><given-names>P</given-names></name><name><surname>Guerrero-Luduena</surname><given-names>R</given-names></name></person-group><article-title>Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain</article-title><source>Vaccines (Basel)</source><year>2022</year><volume>10</volume><issue>2</issue><fpage>176</fpage><pub-id pub-id-type="doi">10.3390/vaccines10020176</pub-id><pub-id pub-id-type="pmid">35214635</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Ruiz-Arag&#x000f3;n J, M&#x000e1;rquez-Pel&#x000e1;ez S, Gani R, Alvarez P, Guerrero-Luduena R. Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain. Vaccines (Basel). 2022;10(2):176.<pub-id pub-id-type="pmid">35214635</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Redondo</surname><given-names>E</given-names></name><name><surname>Drago</surname><given-names>G</given-names></name><name><surname>Lopez-Belmonte</surname><given-names>JL</given-names></name><name><surname>Guillen</surname><given-names>JM</given-names></name><name><surname>Bricout</surname><given-names>H</given-names></name><name><surname>Alvarez</surname><given-names>FP</given-names></name><etal/></person-group><article-title>Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><issue>36</issue><fpage>5138</fpage><lpage>5145</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.07.048</pub-id><pub-id pub-id-type="pmid">34344553</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Redondo E, Drago G, Lopez-Belmonte JL, Guillen JM, Bricout H, Alvarez FP, et al. Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine. Vaccine. 2021;39(36):5138&#x02013;45.<pub-id pub-id-type="pmid">34344553</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Caro</surname><given-names>JJ</given-names></name><name><surname>Briggs</surname><given-names>AH</given-names></name><name><surname>Siebert</surname><given-names>U</given-names></name><name><surname>Kuntz</surname><given-names>KM</given-names></name></person-group><article-title>Modeling good research practices&#x02013;overview: a report of the ISPOR-SMDM modeling Good Research practices Task Force&#x02013;1</article-title><source>Value Health</source><year>2012</year><volume>15</volume><issue>6</issue><fpage>796</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1016/j.jval.2012.06.012</pub-id><pub-id pub-id-type="pmid">22999128</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices&#x02013;overview: a report of the ISPOR-SMDM modeling Good Research practices Task Force&#x02013;1. Value Health. 2012;15(6):796&#x02013;803.<pub-id pub-id-type="pmid">22999128</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Pitman</surname><given-names>R</given-names></name><name><surname>Fisman</surname><given-names>D</given-names></name><name><surname>Zaric</surname><given-names>GS</given-names></name><name><surname>Postma</surname><given-names>M</given-names></name><name><surname>Kretzschmar</surname><given-names>M</given-names></name><name><surname>Edmunds</surname><given-names>J</given-names></name><etal/></person-group><article-title>Dynamic transmission modeling: a report of the ISPOR-SMDM modeling Good Research practices Task Force Working Group-5</article-title><source>Med Decis Mak</source><year>2012</year><volume>32</volume><issue>5</issue><fpage>712</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1177/0272989X12454578</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM modeling Good Research practices Task Force Working Group-5. Med Decis Mak. 2012;32(5):712&#x02013;21.</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>M</given-names></name><name><surname>Russell</surname><given-names>LB</given-names></name><name><surname>Paltiel</surname><given-names>AD</given-names></name><name><surname>Chambers</surname><given-names>M</given-names></name><name><surname>McEwan</surname><given-names>P</given-names></name><name><surname>Krahn</surname><given-names>M</given-names></name></person-group><article-title>Conceptualizing a model: a report of the ISPOR-SMDM modeling Good Research practices Task Force-2</article-title><source>Med Decis Mak</source><year>2012</year><volume>32</volume><issue>5</issue><fpage>678</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1177/0272989X12454941</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM modeling Good Research practices Task Force-2. Med Decis Mak. 2012;32(5):678&#x02013;89.</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Siebert</surname><given-names>U</given-names></name><name><surname>Alagoz</surname><given-names>O</given-names></name><name><surname>Bayoumi</surname><given-names>AM</given-names></name><name><surname>Jahn</surname><given-names>B</given-names></name><name><surname>Owens</surname><given-names>DK</given-names></name><name><surname>Cohen</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3</article-title><source>Value Health</source><year>2012</year><volume>15</volume><issue>6</issue><fpage>812</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1016/j.jval.2012.06.014</pub-id><pub-id pub-id-type="pmid">22999130</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3. Value Health. 2012;15(6):812&#x02013;20.<pub-id pub-id-type="pmid">22999130</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez Bastida</surname><given-names>J</given-names></name><name><surname>Oliva</surname><given-names>J</given-names></name><name><surname>Anto&#x000f1;anzas</surname><given-names>F</given-names></name><name><surname>Garc&#x000ed;a-Alt&#x000e9;s</surname><given-names>A</given-names></name><name><surname>Gisbert</surname><given-names>R</given-names></name><name><surname>Mar</surname><given-names>J</given-names></name><etal/></person-group><article-title>Propuesta De gu&#x000ed;a para la evaluaci&#x000f3;n econ&#x000f3;mica aplicada a las tecnolog&#x000ed;as sanitarias</article-title><source>Gac Sanit</source><year>2010</year><volume>24</volume><issue>2</issue><fpage>154</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.gaceta.2009.07.011</pub-id><pub-id pub-id-type="pmid">19959258</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">L&#x000f3;pez Bastida J, Oliva J, Anto&#x000f1;anzas F, Garc&#x000ed;a-Alt&#x000e9;s A, Gisbert R, Mar J, et al. Propuesta De gu&#x000ed;a para la evaluaci&#x000f3;n econ&#x000f3;mica aplicada a las tecnolog&#x000ed;as sanitarias. Gac Sanit. 2010;24(2):154&#x02013;70.<pub-id pub-id-type="pmid">19959258</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="book"><person-group person-group-type="author"><name><surname>Comit&#x000e9;</surname></name></person-group><source>Asesor para la Financiaci&#x000f3;n de la Prestaci&#x000f3;n Farmac&#x000e9;utica del Sistema Nacional de Salud</source><year>2023</year><publisher-name>Gu&#x000ed;a de evaluaci&#x000f3;n econ&#x000f3;mica de medicamentos.</publisher-name></element-citation><mixed-citation id="mc-CR41" publication-type="book">Comit&#x000e9;. Asesor Para La Financiaci&#x000f3;n De La Prestaci&#x000f3;n Farmac&#x000e9;utica Del Sistema Nacional De Salud. Gu&#x000ed;a de evaluaci&#x000f3;n econ&#x000f3;mica de medicamentos.; 2023.</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Jefferson</surname><given-names>T</given-names></name><name><surname>Di Pietrantonj</surname><given-names>C</given-names></name><name><surname>Al-Ansary</surname><given-names>LA</given-names></name><name><surname>Ferroni</surname><given-names>E</given-names></name><name><surname>Thorning</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>RE</given-names></name></person-group><article-title>Vaccines for preventing influenza in the elderly</article-title><source>Cochrane Database Syst Rev</source><year>2010</year><volume>2</volume><issue>2</issue><fpage>Cd004876</fpage></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;2(2):Cd004876.</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Hollmann</surname><given-names>M</given-names></name><name><surname>Garin</surname><given-names>O</given-names></name><name><surname>Galante</surname><given-names>M</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Dominguez</surname><given-names>A</given-names></name><name><surname>Alonso</surname><given-names>J</given-names></name></person-group><article-title>Impact of influenza on health-related quality of life among confirmed (H1N1)2009 patients</article-title><source>PLoS ONE.</source><year>2013</year><volume>8</volume><issue>3</issue><fpage>e60477</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0060477</pub-id><pub-id pub-id-type="pmid">23555979</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Hollmann M, Garin O, Galante M, Ferrer M, Dominguez A, Alonso J. Impact of influenza on health-related quality of life among confirmed (H1N1)2009 patients. PLoS ONE. 2013;8(3):e60477.<pub-id pub-id-type="pmid">23555979</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Eddy</surname><given-names>DM</given-names></name><name><surname>Hollingworth</surname><given-names>W</given-names></name><name><surname>Caro</surname><given-names>JJ</given-names></name><name><surname>Tsevat</surname><given-names>J</given-names></name><name><surname>McDonald</surname><given-names>KM</given-names></name><name><surname>Wong</surname><given-names>JB</given-names></name></person-group><article-title>Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices Task Force-7</article-title><source>Med Decis Mak</source><year>2012</year><volume>32</volume><issue>5</issue><fpage>733</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1177/0272989X12454579</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices Task Force-7. Med Decis Mak. 2012;32(5):733&#x02013;43.</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Vallejo-Torres</surname><given-names>L</given-names></name><name><surname>Garc&#x000ed;a-Lorenzo</surname><given-names>B</given-names></name><name><surname>Serrano-Aguilar</surname><given-names>P</given-names></name></person-group><article-title>Estimating a cost-effectiveness threshold for the Spanish NHS</article-title><source>Health Econ</source><year>2018</year><volume>27</volume><issue>4</issue><fpage>746</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1002/hec.3633</pub-id><pub-id pub-id-type="pmid">29282798</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Vallejo-Torres L, Garc&#x000ed;a-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27(4):746&#x02013;61.<pub-id pub-id-type="pmid">29282798</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Sacrist&#x000e1;n</surname><given-names>JA</given-names></name><name><surname>Oliva</surname><given-names>J</given-names></name><name><surname>Campillo-Artero</surname><given-names>C</given-names></name><name><surname>Puig-Junoy</surname><given-names>J</given-names></name><name><surname>Pinto-Prades</surname><given-names>JL</given-names></name><name><surname>Dilla</surname><given-names>T</given-names></name><etal/></person-group><article-title>What is an efficient health intervention in Spain in 2020?</article-title><source>Gac Sanit</source><year>2019</year><volume>34</volume><issue>2</issue><fpage>189</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.gaceta.2019.06.007</pub-id><pub-id pub-id-type="pmid">31558385</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Sacrist&#x000e1;n JA, Oliva J, Campillo-Artero C, Puig-Junoy J, Pinto-Prades JL, Dilla T, et al. What is an efficient health intervention in Spain in 2020? Gac Sanit. 2019;34(2):189&#x02013;93.<pub-id pub-id-type="pmid">31558385</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Demicheli</surname><given-names>V</given-names></name><name><surname>Jefferson</surname><given-names>T</given-names></name><name><surname>Di Pietrantonj</surname><given-names>C</given-names></name><name><surname>Ferroni</surname><given-names>E</given-names></name><name><surname>Thorning</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Vaccines for preventing influenza in the elderly</article-title><source>Cochrane Database Syst Rev</source><year>2018</year><volume>2</volume><issue>2</issue><fpage>Cd004876</fpage><pub-id pub-id-type="pmid">29388197</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Demicheli V, Jefferson T, Di Pietrantonj C, Ferroni E, Thorning S, Thomas RE, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2018;2(2):Cd004876.<pub-id pub-id-type="pmid">29388197</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname><given-names>FP</given-names></name><name><surname>Petitjean</surname><given-names>A</given-names></name><name><surname>Nealon</surname><given-names>J</given-names></name><name><surname>Hollingsworth</surname><given-names>R</given-names></name><name><surname>L&#x000f3;pez-Belmonte</surname><given-names>JL</given-names></name></person-group><article-title>Cost-effectiveness analysis has to consider all available evidence when informing inputs</article-title><source>Hum Vaccin Immunother</source><year>2021</year><volume>17</volume><issue>3</issue><fpage>694</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1080/21645515.2020.1799670</pub-id><pub-id pub-id-type="pmid">32961079</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Alvarez FP, Petitjean A, Nealon J, Hollingsworth R, L&#x000f3;pez-Belmonte JL. Cost-effectiveness analysis has to consider all available evidence when informing inputs. Hum Vaccin Immunother. 2021;17(3):694&#x02013;5.<pub-id pub-id-type="pmid">32961079</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>DeMarcus</surname><given-names>L</given-names></name><name><surname>Shoubaki</surname><given-names>L</given-names></name><name><surname>Federinko</surname><given-names>S</given-names></name></person-group><article-title>Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017&#x02013;2018 influenza season</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><issue>30</issue><fpage>4015</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.06.004</pub-id><pub-id pub-id-type="pmid">31201055</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">DeMarcus L, Shoubaki L, Federinko S. Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017&#x02013;2018 influenza season. Vaccine. 2019;37(30):4015&#x02013;21.<pub-id pub-id-type="pmid">31201055</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Izurieta</surname><given-names>HS</given-names></name><name><surname>Chillarige</surname><given-names>Y</given-names></name><name><surname>Kelman</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Relative effectiveness of cell-cultured and Egg-based Influenza vaccines among Elderly persons in the United States, 2017&#x02013;2018</article-title><source>J Infect Dis</source><year>2019</year><volume>220</volume><issue>8</issue><fpage>1255</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy716</pub-id><pub-id pub-id-type="pmid">30561688</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative effectiveness of cell-cultured and Egg-based Influenza vaccines among Elderly persons in the United States, 2017&#x02013;2018. J Infect Dis. 2019;220(8):1255&#x02013;64.<pub-id pub-id-type="pmid">30561688</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Bruxvoort</surname><given-names>KJ</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Ackerson</surname><given-names>B</given-names></name><name><surname>Tanenbaum</surname><given-names>HC</given-names></name><name><surname>Sy</surname><given-names>LS</given-names></name><name><surname>Gandhi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017&#x02013;2018</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><issue>39</issue><fpage>5807</fpage><lpage>5811</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.08.024</pub-id><pub-id pub-id-type="pmid">31445771</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Bruxvoort KJ, Luo Y, Ackerson B, Tanenbaum HC, Sy LS, Gandhi A, et al. Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017&#x02013;2018. Vaccine. 2019;37(39):5807&#x02013;11.<pub-id pub-id-type="pmid">31445771</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Izurieta</surname><given-names>HS</given-names></name><name><surname>Chillarige</surname><given-names>Y</given-names></name><name><surname>Kelman</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Relative effectiveness of Influenza vaccines among the United States Elderly, 2018&#x02013;2019</article-title><source>J Infect Dis</source><year>2020</year><volume>222</volume><issue>2</issue><fpage>278</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiaa080</pub-id><pub-id pub-id-type="pmid">32100009</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative effectiveness of Influenza vaccines among the United States Elderly, 2018&#x02013;2019. J Infect Dis. 2020;222(2):278&#x02013;87.<pub-id pub-id-type="pmid">32100009</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Cumpston</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Page</surname><given-names>MJ</given-names></name><name><surname>Chandler</surname><given-names>J</given-names></name><name><surname>Welch</surname><given-names>VA</given-names></name><name><surname>Higgins</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions</article-title><source>Cochrane Database Syst Rev</source><year>2019</year><volume>10</volume><issue>10</issue><fpage>ED000142</fpage><pub-id pub-id-type="pmid">31643080</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):ED000142.<pub-id pub-id-type="pmid">31643080</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">European Center for Disease Control. Systematic review update on the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratoryconfirmed influenza in individuals aged 18 years and over. 2024.</mixed-citation></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Domnich</surname><given-names>A</given-names></name><name><surname>Arata</surname><given-names>L</given-names></name><name><surname>Amicizia</surname><given-names>D</given-names></name><name><surname>Puig-Barber&#x000e0;</surname><given-names>J</given-names></name><name><surname>Gasparini</surname><given-names>R</given-names></name><name><surname>Panatto</surname><given-names>D</given-names></name></person-group><article-title>Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><issue>4</issue><fpage>513</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.12.011</pub-id><pub-id pub-id-type="pmid">28024956</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Domnich A, Arata L, Amicizia D, Puig-Barber&#x000e0; J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine. 2017;35(4):513&#x02013;20.<pub-id pub-id-type="pmid">28024956</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Beran</surname><given-names>J</given-names></name><name><surname>Reynales</surname><given-names>H</given-names></name><name><surname>Poder</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>CY</given-names></name><name><surname>Pitisuttithum</surname><given-names>P</given-names></name><name><surname>Yuan</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study</article-title><source>Lancet Infect Dis</source><year>2021</year><volume>21</volume><issue>7</issue><fpage>1027</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30694-0</pub-id><pub-id pub-id-type="pmid">33577767</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Beran J, Reynales H, Poder A, Yu CY, Pitisuttithum P, Yuan LL, et al. Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study. Lancet Infect Dis. 2021;21(7):1027&#x02013;37.<pub-id pub-id-type="pmid">33577767</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>JK</given-names></name><name><surname>Samson</surname><given-names>SI</given-names></name><name><surname>Nealon</surname><given-names>J</given-names></name><etal/></person-group><article-title>Letter to editor regarding the systematic review and meta-analysis by Coleman. on the effectiveness of MF59-adjuvanted seasonal influenza vaccine in older adults</article-title><source>Influenza Other Respir Viruses.</source><year>2021</year><volume>15</volume><issue>6</issue><fpage>826</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1111/irv.12891</pub-id><pub-id pub-id-type="pmid">34342136</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Yin JK, Samson SI, Nealon J, et al. Letter to editor regarding the systematic review and meta-analysis by Coleman. on the effectiveness of MF59-adjuvanted seasonal influenza vaccine in older adults. Influenza Other Respir Viruses. 2021;15(6):826&#x02013;7.<pub-id pub-id-type="pmid">34342136</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Okoli</surname><given-names>GN</given-names></name><name><surname>Racovitan</surname><given-names>F</given-names></name><name><surname>Abdulwahid</surname><given-names>T</given-names></name><name><surname>Righolt</surname><given-names>CH</given-names></name><name><surname>Mahmud</surname><given-names>SM</given-names></name></person-group><article-title>Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: a systematic review and meta-analysis of the evidence from test-negative design studies after the 2009/10 influenza pandemic</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><issue>8</issue><fpage>1225</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.01.032</pub-id><pub-id pub-id-type="pmid">33494964</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Okoli GN, Racovitan F, Abdulwahid T, Righolt CH, Mahmud SM. Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: a systematic review and meta-analysis of the evidence from test-negative design studies after the 2009/10 influenza pandemic. Vaccine. 2021;39(8):1225&#x02013;40.<pub-id pub-id-type="pmid">33494964</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Fens</surname><given-names>T</given-names></name><name><surname>Boer</surname><given-names>PT</given-names></name><name><surname>Puijenbroek</surname><given-names>EPV</given-names></name><name><surname>Postma</surname><given-names>MJ</given-names></name></person-group><article-title>Inclusion of safety-related issues in economic evaluations for Seasonal Influenza vaccines: a systematic review</article-title><source>Vaccines (Basel).</source><year>2021</year><volume>9</volume><issue>2</issue><fpage>111</fpage><pub-id pub-id-type="doi">10.3390/vaccines9020111</pub-id><pub-id pub-id-type="pmid">33540633</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Fens T, Boer PT, Puijenbroek EPV, Postma MJ. Inclusion of safety-related issues in economic evaluations for Seasonal Influenza vaccines: a systematic review. Vaccines (Basel). 2021;9(2):111.<pub-id pub-id-type="pmid">33540633</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>DiazGranados</surname><given-names>CA</given-names></name><name><surname>Denis</surname><given-names>M</given-names></name><name><surname>Plotkin</surname><given-names>S</given-names></name></person-group><article-title>Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials</article-title><source>Vaccine</source><year>2012</year><volume>31</volume><issue>1</issue><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.084</pub-id><pub-id pub-id-type="pmid">23142300</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012;31(1):49&#x02013;57.<pub-id pub-id-type="pmid">23142300</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Govaert</surname><given-names>TME</given-names></name><name><surname>Thijs</surname><given-names>CTMCN</given-names></name><name><surname>Masurel</surname><given-names>N</given-names></name><name><surname>Sprenger</surname><given-names>MJW</given-names></name><name><surname>Dinant</surname><given-names>GJ</given-names></name><name><surname>Knottnerus</surname><given-names>JA</given-names></name></person-group><article-title>The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial</article-title><source>JAMA</source><year>1994</year><volume>272</volume><issue>21</issue><fpage>1661</fpage><lpage>1665</lpage><pub-id pub-id-type="doi">10.1001/jama.1994.03520210045030</pub-id><pub-id pub-id-type="pmid">7966893</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Govaert TME, Thijs CTMCN, Masurel N, Sprenger MJW, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA. 1994;272(21):1661&#x02013;5.<pub-id pub-id-type="pmid">7966893</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JKH</given-names></name><name><surname>Lam</surname><given-names>GKL</given-names></name><name><surname>Shin</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Krishnan</surname><given-names>A</given-names></name><name><surname>Greenberg</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis</article-title><source>Expert Rev Vaccines</source><year>2018</year><volume>17</volume><issue>5</issue><fpage>435</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1080/14760584.2018.1471989</pub-id><pub-id pub-id-type="pmid">29715054</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Lee JKH, Lam GKL, Shin T, Kim J, Krishnan A, Greenberg DP, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines. 2018;17(5):435&#x02013;43.<pub-id pub-id-type="pmid">29715054</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Puig-Barber&#x000e0;</surname><given-names>J</given-names></name><name><surname>Natividad-Sancho</surname><given-names>A</given-names></name><name><surname>Calabuig-P&#x000e9;rez</surname><given-names>J</given-names></name><name><surname>Lluch-Rodrigo</surname><given-names>JA</given-names></name><name><surname>Pastor-Villalba</surname><given-names>E</given-names></name><name><surname>Mart&#x000ed;nez-&#x000da;beda</surname><given-names>S</given-names></name><etal/></person-group><article-title>MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><issue>37</issue><fpage>3995</fpage><lpage>4002</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.05.070</pub-id><pub-id pub-id-type="pmid">23731629</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Puig-Barber&#x000e0; J, Natividad-Sancho A, Calabuig-P&#x000e9;rez J, Lluch-Rodrigo JA, Pastor-Villalba E, Mart&#x000ed;nez-&#x000da;beda S, et al. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. Vaccine. 2013;31(37):3995&#x02013;4002.<pub-id pub-id-type="pmid">23731629</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Izurieta</surname><given-names>HS</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Kelman</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Lindaas</surname><given-names>A</given-names></name><name><surname>Loc</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comparative effectiveness of Influenza vaccines among US Medicare beneficiaries Ages 65 years and older during the 2019&#x02013;2020 season</article-title><source>Clin Infect Dis</source><year>2021</year><volume>73</volume><issue>11</issue><fpage>e4251</fpage><lpage>4259</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1727</pub-id><pub-id pub-id-type="pmid">33211809</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Izurieta HS, Lu M, Kelman J, Lu Y, Lindaas A, Loc J, et al. Comparative effectiveness of Influenza vaccines among US Medicare beneficiaries Ages 65 years and older during the 2019&#x02013;2020 season. Clin Infect Dis. 2021;73(11):e4251-4259.<pub-id pub-id-type="pmid">33211809</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>